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ABSTRACT
Yan, Xiaowei. Ph.D. The University of Memphis, August, 2010. Stochastic and
State Space Models of Carcinogenesis under Complex Situation. Major Professor: WaiYuan Tan, Ph. D.
With more and more biological mechanisms of cancer development being
discovered, in order to improve cancer control and prevention, it becomes necessary to
develop effective and efficient mathematical and statistical models and methods to
incorporate the biological information, and to identify critical events in the process of
carcinogenesis. In this dissertation, the complex nature of carcinogenesis has been
represented by stochastic system model; combining this model with information from
observations and prior knowledge, we have developed state space models to evaluate
cancer gene mutations and cell proliferation at different cancer development stages. Also,
we have proposed a generalized Bayesian method via multi-level Gibbs sampling
procedure to predict state (stage) variables of the models.
In this dissertation, stochastic models have been proposed for initiation, promotion
and complete carcinomas experiments; these experiments are most commonly performed
in cancer risk assessment of environmental agents. These stochastic models are simple
multi-pathway models which are constructed based on biological mechanisms. The
estimates we obtained from the models have provided quantitative evaluation of dose
related mutation rates of major genes and cells proliferation rates; these results could be
used to assess the risk of developing malignant tumor in the environment we live.
More complicated stochastic and state space models have been developed for
sporadic human colon cancer and for hereditary and non-hereditary human liver cancer.
We have utilized the proposed models to fit to Surveillance Epidemiology and End
iii

Results (SEER) data. The results imply that our models have effectively incorporated
biological information and observations; these models fitted the data very well and the
inferences based on estimate were very consistent with biological findings. Furthermore,
the models reflected the complex nature of carcinogenesis. We notice that many cancers
are developed through multiple-stage multiple-pathway. Our analyses of colon cancer
and liver cancer have showed that some pathways are more devastated than others. This
suggests thus it would be more efficient to intervene or treat the critical events in the
more devastated pathways.
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1. INTRODUCTION

Recent studies by cancer molecular biologists and cancer geneticists have shown that
in most practical situations, the process of carcinogenesis is very complex.
First, the process of carcinogenesis may not be time homogeneous; this is especially
true in cancer initiation and promotion experiments and in animal carcinogenicity
experiments as those conducted by scientists at EPA. (Many other biological and
epidemiological evidences can be found in papers in the NCI Symposium (1985) and in
Tan and Chen (1995)).
Second, in most cases the same cancer is developed by several different pathways
(Tan, 1991; Tan & Chen, 1991, 1998, 2000, 2005; Weinberg, 2007); this includes, for
example, colorectal cancer, liver cancer, lung cancer, and melanoma among many others.
Third, inheritance and heredity is an important factor in carcinogenesis. For
example, family cancer history may predict cancer development speed among breast
cancers in women, and FAP and HNPCC are well known inherited cancer cases in human
colon cancers. Also, pediatric cancers give cancer cases for new born babies, contributing
to pediatric cancer cases. Examples of pediatric cancer cases include medulloblastoma,
retinoblastoma, hepatoblastoma, pediatric lung cancer and rhabdomyosarcoma.
Fourth, it is well recognized that for most of the cancers, the process of
carcinogenesis involves a large number of cancer genes (5 to 10 genes in most cases
(Hopkin, 1996), but as many as 200 genes may have been involved in the origin of all
leukemia; see Greaves, 1997). It follows that in many cases, three or more stages may be
more appropriate to represent the true biologically supported stochastic models of
carcinogenesis. For example, as demonstrated by Little and his associates (Little, 1995,
1

1996; Little, Murihead, Boice, & Kleinerman, 1995; Little, Muirhead, & Stiller, 1996) for
cancers from Japanese atomic bomb survivors and radiation-induced leukemia,
carcinogenesis is better described by three-stage models than by two-stage models
although the same data can be fitted equally well by a three stage model as by a two-stage
model.
The purpose of the dissertation is to develop stochastic and state space models for
cancer development under complex situation.
In Chapter 1, we summarize the traditional stochastic models for carcinogenesis, and
discuss the difficulties and disadvantages of the traditional stochastic models and the
traditional approaches. Then we briefly introduce the biologically supported stochastic
and state space models under realistic complex conditions. Next, some generalized
Bayesian procedures are discussed for estimating parameters and for predicting state
variables.
In Chapter 2, a set of stochastic models are proposed for initiation-promotion
experiments, which are commonly used by researchers to assess cancer risk of
environmental agents. It this chapter we propose a simple two pathways model involving
a generalized one stage model and a generalized two-stage model for the generation of
papillomas and carcinomas from these experiments.
In Chapter 3, the stochastic and state space models are proposed for human
colorectal cancer. These models involve 2 pathways, with one pathway being a 4-stage
model and the other pathway being a 5-stage model. Through fitting of the SEER data,
we showed that the model we proposed was more appropriate than existing singlepathway models.
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In Chapter 4, we discuss some stochastic and state space models for adult liver
cancer (Hepatocarcinoma, HCC) and for pediatric liver cancer (hepatoblastoma), the
latter of which incorporating hereditary segregation of genes.
In Chapter 5, we give a brief summary of our work and propose some future
research.
Quantitative Carcinogenesis Modeling
The first sets of mathematical carcinogensis models, reflecting essential biological
processes via pathway from a normal stem cells to a cancer cells, were proposed in 1950s
(Nordling, 1953). Amitage-Doll model (Amitage & Doll, 1954) may be the best known
model among them, which gave the age-specific incidence of many carcinomas, and also
connected rate-limiting steps to the mathematical model. The model assumes that cancer
cells are developed from a single stem cell through a series irreversible, heritable events,
which are mutations related. However, the model completely ignores cell proliferation
and differentiation of intermediate cells. In 1979 Moolgavkar and Venzon and in 1981
Moolgavkar and Knudson proposed a 2-stage model, called MVK-model, in which a
cancer tumor is developed from a single normal stem cell by clonal expansion, and
carcinogensis is taken as the end result of two discrete, heritable and irreversible events.
This model became the most commonly used to fit different type of carcinomas since
then (Moolgavkar, Dewanji, & Venzon, 1988; Moolgarvkar & Luebeck, 1989; Portier &
Bailer, 1989). The major limits of the model are:
(1) It assumes that tumor is developed instantaneously from initiated cells at the last
stage, which usually is not true. If this assumption is violated, then the number of cancer
tumors is no longer Markov because it depends on the time when the last-stage initiated
3

cells are generated. In this case, Markov theories cannot be applied to cancer tumor (Tan
& Chen, 1998).
(2)

It has been well accepted that most of cancer tumors are developed through

more than two stages, some cancer tumors are even compilcated, developing through
multiple-pathway, and each pathway contains mutilple stages. So that two-stage model is
obviously too simple to describe carcinogenesis (Tan, 2002).
(3) It is extremely hard to adopt the model to multiple-pathway multiple-stage
carcinogenesis because the mathematical results become too complicated (Tan, 1991).
(4) Not all parameters could be identified from the incidence function and the
probability distribution of time to tumors, because function of parameters instead of
separate parameters is involved in the incidence function and the probability distribution.
To overcome the limits and difficulties of the MVK-model, we proposed an
alternative approach, in which stochastic equations were used to represent the biological
and genetic information of carcinogenesis, and a statistical model was used to represent
observation. By combining these models and information from other sources, we were
able to estimate all parameters and state variables, and also provide biologically reliable
interpretation.
Many biological evidences have been reported to support cancer cells are developed
through multiple pathways (Weinberg, 2007). Before discussing the detail of the new
model we proposed and applied in multiple-pathway carcinogenesis, we would like to
briefly review MVK model by applying it for a simplest multiple-pathway carcinogensis,
which can be taken as an extended MVK two-stage model. Through the assumptions and
model construction, the limits and difficulties of MVK model were revealed. Then we
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introduced our approach to see the new approach has many advantages over the extended
MVK model.
We started with a simple multiple-pathway model (called extended MVK model).
The regular MVK two-stage model of carcinogenesis assumes three types of cancer cells:
The normal stem cells, the intermediate cells and the tumor cells. It also assumes that
with probability one, a tumor cell will develop into malignant tumor. We denote three
types of cancer cells by N(t), I(t) and T(t) at time t, respectively. In the extended MVK
model, instead, two intermediate cells I1 and I2 cells are present.

Figure 1. A Simple Multiple-Pathway Model
As shown in Figure 1, the extended MVK model involves a one-stage model and a
three-stage model. In this model, a cancer tumor develops either by normal cells N to
tumor cells T directly, or by normal cells N to tumor cells T via I1 and I2 cells. Note that
because mutation rates are usually very small, in order that tumor cells can develop
through three-stage pathway, the one-stage pathway must be a rare event too, which is
actually consistent with a lot observations (Land, Parada, & Weinberg, 1983; Schwab,
Varmus, & Bishop, 1985; Tan, 2001; Tan & Chen, 1998; Yancopoulos et al., 1984).
5

Let N(t), I1(t), I2(t) and T(t) be the number of normal stem cells, I1 cells, I2 cells and
cancer tumor cells at time t, respectively. To derive mathematical procedures for the
model shown in Figure 1, we make the following assumptions. Most of the assumptions
are the same as for MVK two-stage model.
1. At the time t0 of birth, N(t0) = N0 is very large (N0 ≤ 108). This assumption usually
holds for most of tissues (Moolgarkar & Knudson, 1981).
2. The Ij, j=1, 2 cells follow a nonhomogeneous Feller-Arley birth-death process for
cell proliferation and cell differentiation with birth rate bj(t) and death rate dj(t).
3. Given that the cancer tumors developed from normal stem cells by one-stage
pathway, (N → T), we assume that the probability that a normal stem cell at time t
produces one normal stem cells and one tumor cell at time t + Δt is γ(t) Δt + o(Δt).
Similarly, given the three-stage pathway N → I1 →I2 → T, we assume that the probability
of a normal cell producing one normal cell and one I1 cell at time t + Δt is α1(t)Δt + o(Δt).
And the probability that an I1 cell at time t produces one I1 cell and one I2 cell at time t +
Δt is ω1(t)Δt + o(Δt). The probability of I2 cell yields one I2 cell and one tumor cell at
time t + Δt is β1(t)Δt + o(Δt).
4. As in Moolgavkar and Knudson (1981) and Tan and Brown (1987), we assume
that the time require for the development of tumors from tumor cells is very short
compared with the time cancer tumors developed from normal stem cells. This implies
that with probability one tumor cells grow into tumors and that random variation for the
time between the initiated tumor cells and cancer tumors is ignored.
5. The birth-death processes and the mutation processes are independent of one
another and each cell goes through the above processes independently of other cells.

6

Given above assumptions, it follows that:
(1) The processes is basically a Markov process
(2) Since the mutation rates are very small (10-8 ~ 10-6), also because in most cases
the birth rates are greater than death rates for normal cells (Buick & Pollack, 1984), the
number of normal cells is very large for all t ≥ t0. In that case, we assume the number of
normal cells (N(t)) is a deterministic function. And because of mutation rates are very
small so that N(t)γ(t) and N(t)α1(t) are expected to be finite. If N(t)γ(t) and N(t)α1(t) are
finite for all t ≥ t0, it is reasonable to assume that during [t, t + Δt) the mutation processes
from normal cells to tumor cells (one-stage pathway), to I1 cells follow Poisson processes
with parameters N(t)γ(t)Δt + o(Δt) and N(t)α1(t)Δt + o(Δt).
(3) As shown in Tan and Brown (1987), if the normal stem cells follow
nonhomogeneous Feller-Arley Birth-death processes with birth rate bN(t) and death rate
dN(t), then from above assumption (2)-(5), {N(t), Ii(t), i = 1, 2, T(t)} form a continuous
time multiple branching process, with rates of bN(tj)Δt + o(Δt), dN(tj)Δt + o(Δt) for normal
stem cells; bi(tj)Δt + o(Δt), bi(tj)Δt + o(Δt), in which {i = 1, 2; j =0, 1, 2, …, n}, for Ii
cells; and 1+ o(Δt) for tumor cells.
In MVK model, the traditional procedures to obtain the incidence function are:
First, derive the probability generating function (PGF) of the number of intermediate
initiated cells and cancer tumors through Kolmogorov forward equation.
Second, use the PGF to obtain cancer incidence function and the probability
distribution of the number of tumors.
We will show the traditional procedures for the simple two-pathway model.
Let:
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P1(I, ju, u=1,2, k; t) be the conditional probability of [N(t) = I, Iu(t) = ju, T(t) = k
|N(t0) = N0] ,
P2(j1,j2, k; t) the conditional probability of [I1(t) = j1, I2(t) = j2, T(t) = k | I1(t0) = 1].
and P3(j, k; t) the conditional probability of [I2(t0) = j, T(t) = k | I2(t0) = 1].
Let η(x, y1, y2, z; t0, t) = η(t0, t) be the PGF of [N(t), I1(t), I2(t), T(t) | N(t0) = N0];
η(1, y1, y2, z; t0, t) = (x, y1, y2, z; t0, t) =
N(t0)=N0] ; and g(z; t0, t) =

(t0, t) the PGF of [I1(t), I2(t), T(t) |

(1, 1, 1, z; t0, t) the PGF of [T(t) | N(t0)= N0].

Let ζ1(y1,y2, z; t0, t) = ζ1(t0, t) be the PGF of [I1(t), I2(t), T(t) | I1(t0)=1], and (y2, z;
t0, t) = (t0, t) the PGF of [I2(t), T(t) | I2(t0) = 1].
Then
∑∑ ∑ ∑ xy

η t ,t

∑ ∑ ∑ y

ζ t ,t

y

y

z P i, j , j , k; t

(1.1)

z P j , j , k; t

(1.2)

and
∑ ∑ y z P j, k; t

t ,t

(1.3)

Because the processes are Markov processes, we can write down the Kolmogorov
forward equations for the above conditional probabilities by using standard procedures.
Using transition probability given in Table 1, the Kolmogorov forward equations are:
, , , ;
∑

1, , , ;
1, ,

1

1, , , ;

1

1, ,
,

, ;

1, , ;

, ;

1
1
, , , ;

, , , ;
, , , ;

(1.4)

and
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1
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1

,

1;
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(1.5)

and
, ;
,

1

1, ;

1

1;

1, ;

, , ;

(1.6)

The initial conditions are:
, , , ;

; i, j1, j2, k = 0, 1, 2…

, , ;
, ;

, i = 1, 2 and j1, j2, k = 0, 1, 2…
; j, k = 0, 1, 2…

Under the assumption (2)-(5), Tan (1991) has shown that ζ

,

and

,

satisfy the following first order partial differential equations:
ζ

,

1

1
1

1
with initial condition ζ

,

and
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ζ
ζ

,

,
(1.7)

Table 1
Transition Probabilities of Simple Two-pathway Model
Cells at time tj

1 N cell

1 I1 cell

1 I2 cell

Cells at time tj+Δt

Probability

2 N Cells

bN(tj)Δt+o(Δt)

0 Cells

dN(tj)Δt+o(Δt)

1 N cell and 1 T cell

γ(tj)Δt+o(Δt)

1 N cell and 1 I1 cell

α1(tj)Δt+o(Δt)

1 N cell

1-[ bN(tj)+ dN(tj)+ γ(tj)+
α1(tj)]Δt+o(Δt)

2 I1 Cells

b1(tj)Δt+o(Δt)

0 Cells

d1(tj)Δt+o(Δt)

1 I1 cell and 1 I2 cell

ω1(tj)Δt+o(Δt)

1 I1 cell

1-[ b1(tj)+ d1(tj)+ ω1(tj)]Δt+o(Δt)

2 I2 Cells

b2(tj)Δt+o(Δt)

0 Cells

d2(tj)Δt+o(Δt)

1 I2 cell and 1 T cell

β1(tj)Δt+o(Δt)

1 I2 cell

1-[ b2(tj)+ d2(tj)+ β1(tj)]Δt+o(Δt)

1 Tumor

1+ o(Δt)

Other Cases

o(Δt)

1 Tumor

,
with initial condition

1
,

1
.
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,

(1.8)

If the normal stem cells follow nonhomogeneous Feller-Arley birth-death process
with birth rate bN(t) and death rate dN(t), then

,

satisfies the following first-order

partial differential equation:
,
1

1

1

1
1

1
with initial condition

,

(1.9)

,
,

and N(t) is a deterministic function, in this case,
; 0,

0

is available for most of
,

important special cases. As shown in Tan (1991), if

,

1

,

The solution of partial differential equation of

then

,

,

,
, if we set t0 = 0,

satisfies the following Ricatti equation with initial condition

:
(1.10)
Then with an assumption that the probability of tumor cell developing to cancer

tumor is one, then solution of above differential equation can be readily solved and the
solution is:
exp
exp

(1.11)

where x2 > x1 are given by 2
4

/

and 2

4
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/

.

,

Though solution of

is available, the solution of ζ

,

,

and

are

extremely difficult even in homogenous cases. We have to add more assumptions to find
the solution. If N(t) is very large, and γ(t) and α1(t) are very small, so that both N(t)γ(t)
and N(t)α1(t) are finite for all t ≥ t0, we can assume Poisson distributions for the number
of mutations from normal stem cells to tumor cells and to I1 cells and also assume
,

. Then as shown in Tan (1991) the solution for

1,

,

, ; ,

is as following:
,

exp

1

ζ

,

1
(1.12)

,

In order to find

, we have to find solution for ζ

, the ζ

Ricatti equation for

,

ζ

,

. Similar as to derive

and set t0 = 0, we have following

Ricatti equation:
ζ
ζ 0

ζ

ζ

, with initial condition

.
In general it is very difficult to solve above differential equation because

is not

linear, thus the whole function is not linear. In order to find close form solution for above
differential equation, we have to add further assumptions or find appropriate
approximation. Moolgavkar and Venzon (1979) assumed d1=0, then above differential
equation of ζ
ζ

becomes:
ζ

ζ

By using linear approximation of
ζ

1

, with initial condition ζ 0

(Taylor expansion), the solution of ζ

y b U t

.
is:

(1.13)
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where
1

and

.

Cancer Incidence Function λ(t)
After obtaining solutions for ζ

, we can further obtain incidence rate λ(t) of tumor

at time t. It has been shown by Tan (1991) that:
1,1,0; , /

1,1,0;

,

(1.14)

where
1,1,0; ,

1,1,0; ,

To the order O(N ):
1,1,0; ,

1,1,0; ,

ζ 1,1,0; ,

1

,
where υ u, t

ζ 1,1,0; u, t

Since ζ y , y , z; t , t

y , so
,

,

and
where ζ

u, t

ζ

,

ζ 1,1,0; u, t and

|

(1.15)
0,

|

1,
0,

1 is the conditional

expected number of I2 cells at time t given T(t) = 0 and I1(u) =1, t ≥ u.
It follows that
ζ

,

|

0,

1
(1.16)
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That is, incidence rate is the function of conditional expected number of the last
stage initiated cells.
From above incidence function, we notice that the product of some mutation rates is
involved in the incidence function, such as

, it is not possible to estimate these

parameters separately. So that even if this model could be applied to estimate parameters,
not all parameters are identifiable.
As we have shown above, three major drawbacks of the MVK model or extended
MVK model are:
Many biological evidences indicated that in most of cases cancer tumor developed
from multiple pathways rather than a single pathway, and each pathway contains more
than two stages. Even we can extend the MVK two-stage to multiple-pathway multipleevent model, it would be extremely difficult to solve partial differential equations
involved in the model, and it is almost not possible to obtain close form of incidence rate.
Even a model is as simple as above, the incidence function has been very difficult to
obtain. We have also shown that in order to find close form of the solutions to differential
equations, we have to have more assumptions, some assumptions are not realistic. For
example, in order to obtain the solution for ζ t , Moolgavkar and Venzon have assumed
d1 = 0.
Even if the close form of incidence function could be derived, we have shown that
many parameters cannot be estimated separately.
The MVK model is based on Markov process, which implies that with probability 1
each cancer cell instantaneously develops into a cancer tumor. This assumption ignores
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tumor progression (birth-death process), which is usually not true in reality (Fakir, Tan,
Hlatky, Hahnfeldt, & Sachs, 2009).
In order to overcome these difficulties and drawbacks, we introduce stochastic and
state space model developed for complex system, which usually contains multiple
pathways, multiple-stage.
Stochastic Equations and State Space Model
Biologists and geneticists have discovered that the same cancer can be developed
through more than one pathway, and that each pathway contains more than two stages.
Along single pathway models, realizing the complex nature of carcinogenesis, Chu
(1985) and Little (1995) have developed generalized multistage stochastic model of
carcinogenesis, extending the two-stage MVK model to models with multiple stages.
These models and the methods were based on Markov process which would need to
assume that the last stage cells grow instantaneously into cancer tumors as soon as they
are generated; in this case, one may identify the last stage cell as cancer tumors (i.e.,
ignoring cancer progression). Unfortunately, in many practical situations, the Markov
assumption is not realistic and gives confusing results (Fakir et al., 2009; Yakovlev &
Tsodikov, 1996; Yang & Chen, 1991), especially in mouse models and in radiation
carcinogenesis. Furthermore, even if the Markov assumption is valid, because it is often
impossible to obtain analytical solutions for partial differential equations of the
probability generating function of stage variables and cancer tumors derived from
Kolmogorov’s forward/backward equations, the methods would need to make many
additional unrealistic assumptions and to drive approximations. Following Yang and
Chen (1991) to postulate that cancer tumor developed by clonal expansion from a
15

primary cancer cell to account for cancer progression, Tan and Chen (1998) have
developed an extended k-stage model and have proposed a stochastic equations approach
to develop mathematical analysis for these models. This extended k-stage model is the
most general model for single pathway and the stochastic equations method is very
powerful and can be used to more complex models involving multiple pathways.
Because many cancers involve multiple pathways, in this section we will propose a
more generalized model involving multiple-pathways. We will illustrate how to construct
this new model and discuss some advantages of the new model. As we will show in
Chapters 3 and 4, these models can be used to fit cancer incidence of human colon cancer
and liver cancer.

Figure 2. Multiple Pathways
In Figure 2, cancer tumor is developed from two pathways; one pathway, called I
pathway, contains k1 stages, and another pathways, called J pathway, contains k2 stages.
We define the Ik1 and Jk2 cells as primary cancer cells, which arise directly from Ik1-1 and
Jk2-1 cells by mutation or genetic changes. Thus, Ik1 and Jk2 arising from other Ik1 and Jk2
16

cells by cell proliferation are called secondary Ik1 andJk2 cells. Therefore, cancer tumors
either derive from primary Ik1 cells or from primary Jk2 cells by stochastic birth-death
process.
We define intermediate stages involved in the multiple-pathway model as discrete,
heritable and irreversible events, denoted by Iu, u = 1, …, k1-1and Jv, v=1, …, k2-1. Iu and
Jv initiated cells arise from (u-1)th stage in I pathway and (v-1)th stage in J pathway by
mutation or genetic changes. Let N denote normal stem cells, and T denote cancer tumors
arising from primary Ik1 andJk2 cells. Then the model assumes that the two pathways are
exclusive, and assumes N→I1→ I2 → … → Ik1 and N→ J1 → J2 → … → Jk2 with Iu and
Jv cells being subject to stochastic birth-death process. Let Iu(t), u = 1, 2, …, k1-1 denote
the number of Iu cells at time t and Jv(t), v = 1, 2, …, k2-1 denote the number of Jv cells at
time t, and T(t) denote the number of malignant cancer tumor at time t. We use

t ={

Iu(t), u = 1, 2, …, k1-1, Jv(t), v = 1, 2, …, k2-1, T(t)} to denote the set of state variables,
and use {bu(t), du(t), αu(t)} represent the birth rate, death rate and mutation rate from Iu →
Iu+1 at time t. Similarly, we use {bv(t), dv(t), βu(t)} denote the birth rate, death rate and
mutation rate from Jv → Jv+1 at time t. That is, at small time interval [t, t+Δt), the
probability that Iu cell will produce two Iu cells, zero Iu cells, and one Iu cell and one Iu+1
cell with probability bu(t)Δt + o(Δt), du(t)Δt + o(Δt), and αu(t)Δt + o(Δt), respectively.
The same to Jv cells. At the last stage, the malignant cancer tumors developed from a
primary Ik1 or Jk2 cell through stochastic birth-death process with birth rate bk1(s1,t) and
death rate dk1(s1,t) for I pathway, and bk2(s2,t) for birth rate and dk2(s2,t) for J pathway,
where s1 and s2 are onset time of Ik1 or Jk2 cell, respectively.

17

To derive the stochastic differential equations for above processes, let
,

denote the number of birth, death, and mutated cells from Iu → Iu+1

,
J

J

J

at time t, and B t , D t , M t

denote the number of birth, death, and mutated cells

from Jv → Jv+1 at time t. Tan (2002) has shown that the conditional probability
,

distribution of

,

|

is multinomial with parameters {Iu(t); bu(t)Δt,

du(t)Δt, αu(t)Δt}. Similarly,
,

,

|

~

,

,

,

, v = 1, 2, …, k2-1.

Then the differential equations for Iu(t), u = 1, 2, …, k1-1 and for Jv(t), v = 1, 2, …,
k2-1 could be obtained from above distributions:
(1.17)

, where

, u = 0, 1,…, k1-1.

The random noises are given by:
ε t

B t

ε t

M

N t b t Δt

D t

N t d t Δt

(1.18)

and
t

I

t α

t Δt

B t

I t b t Δt

D t

I t d t Δt

(1.19)

Based on the distribution, the random noises {ε t , u

0, 1, … , k

1} have

condistional expectation zero. It is also easy to see ε t are uncorrelated with state
variables. The covariance of ε t ’s are also easy to derive, that is, to order o(Δt), the
covariance is:
Cov ε t Δt, ε τ Δt
d t

Δt

δ t

τ E 1

o Δt , and Cov ε t Δt, ε

δ

τ Δt
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I

t α

0 for u

t
w

I t b t
(1.20)

Similar differential equations can be derived for Jv(t) cells, v = 1, 2, …, k2-1.
We also can develop the probability distribution of T(t) by using the I pathway for
illustration . We use PT(s1,t) to represent the probability a primary Iu cell arising at time s1
developing a detectable caner tumor at time t. Assume that cancer tumor is detectable
only if it contains at least NT cancer tumor cells. As shown in Tan (2002), given an Iu cell
arising from Iu-1 cell at time s1, the probability that this Iu cell will produce j Iu cells at
time t is given by:
1

1

(1.21)

1
where

and

Then PT(s1, t) is given by:
PT s , t

∑

NT PM

NT

j

(1.22)

Given this probability, the conditional probability distribution of T(t) given {Ik1-1(τ), τ ≤
t} is a Poisson with parameter:
,

(1.23)

That is,
{T(t) | Ik1-1(τ), t0 ≤ τ ≤ t}~ Poisson {

}
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(1.24)

Similarly, we can derive the conditional probability distribution of T(t) given {Jk21(τ),

τ ≤ t}.
Then, if tumor is developed from I pathway alone, the conditional probability of

producing a detectable cancer tumor during [tj-1, tj) given {Ik1-1(τ), t0 ≤ τ ≤ tj} is:
,
,

,
(1.25)

Similarly, we can derive the probability of detectable tumor developed from J
pathway alone during [tj-1, tj).
Since the cancer tumor is developed from at least one pathway, during [tj-1, tj), the
probability of detectable tumor is developed from at least one pathway is:
,
,

1

1
,

,

1

,

,

,
(1.26)

We have illustrated how to derive the conditional probability of state variables and
cancer incidence function for two pathways. The conditional probability of state variables
and cancer incidence depend on the model structure, for example, single multiple-stage
model, or multiple-pathway multiple-event. No matter what the model structure is
utilized, cancer incidence and conditional probability of state variables can be readily
derived. Tan and Chen (1998) have shown that the model through stochastic differential
equations are equivalent to the classical Markov theory method, that is, intermediate
initiated cells and cancer tumors satisfy the same set of partial differential equations.
Above model has also taken tumor progression of the last stage into consideration, thus
the model is more appropriate in practice.
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The observation model, on the other hand, depends on available data. For example,
in cancer risk assessment studies of environmental agents, the number of animals with
papillomas during [ti,j-1, ti,j) is observed, denoted by M(j); starting with n animals with no
papillomas at t0, then we can construct observation model as following:
~
where

,

;

,

(1.27)

is the probability of developing papillomas during [ti,j-1, ti,j).

The observation model, as shown above, integrates the stochastic model with the
observation. By incorporating differential equations with observations, and information
from other sources, Tan and Chen (1998) proposed state space models of carcinogenesis
for multi-stage models. It combines the basic mechanism and random variation,
represented by stochastic differential equations, with observations (via observation
model). Tan and Zhang (2007) and Tan and Yan (2009) applied the state space models in
several types of cancers to study cancer tumor development. The applications have
shown that state space models have many advantages over traditional stochastic model or
statistical model used alone:
Biologists and geneticists have discovered more and more mechanisms of
carcinogenesis, which provide a rich source in carcinogenesis modeling. The state space
model combines information from different sources, and are easier to adapt to study
different types of cancers.
The state space model can provide reasonable estimation of parameters which
usually cannot be identified by the stochastic model or statistical model alone.
Through Gibbs sampling the state space model can provide an optimal procedure to
estimate unknown parameters and state variables simultaneously.
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The state space model can provide a new avenue to predict cancer incidence in the
future.
We have constructed the state space models for different types of cancers, the details
are shown in the following chapters.
Pathways of Carcinogenesis
Stochastic differential equations are constructed based on pathways involved in
cancer development. In this section, we will briefly introduce pathways of
carcinogenesis.
It has been commonly accepted that carcinogenesis is a multiple-step random
process, and all steps reflect genetic and/or epigenetic changes, which initiate many
mutations and promote proliferation of mutated cells, leading to cancer malignancy
(Nettesheim & Barrett, 1985; Tan, 1991). However, because genetic changes are rare
events and can only occur during cell cycle, it is statistically nearly impossible that all
genetic changes occur during one cell cycle. On the other hand, though genetic changes
can take place in any cell cycle, only certain order of genetic changes can lead to the
completion of cascade of carcinogenesis to generate cancer tumor. The major genetic
changes and their order form genetic pathways of carcinogenesis. For example, in human
colon cancer, a cell with mutated ras oncogene but no other genetic changes would
eventually be eliminated. Thus in colon cancer, mutation of ras gene has never been
observed as an initiated early event. Molecular biological explanation is that though
mutated ras enables the cell to enter cell cycle without growth factor and can also evoke
MAPK pathway and the PI3K-Akt pathway to increase transcription of many genes in
nucleus (Osada & Takahashi, 2002; Weinberg, 2007); however, it can also induce the
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suppressor gene p14ARF to activate p53 gene via ARF-MDM2-p53 pathway, leading to
apoptosis of cell. In contrast, if APC gene is mutated or inactivated, it would generate
chromosome instability and LOH (loss of Heterozygosity) because the APC gene affect
the G2 checking point during mitosis stage by interfering with microtubule and
centrosome coursing aberrant chromosomal segregation, the daughter cells become
aneuploidy or polyploidy (Fodde, Smit, & Clevers, 2001; Green & Kaplan, 2003), which
would increase the fitness of the cells and also speed up mutations or inactivation of other
genes.
Micro-array analyses have indicated that in most human cancers, a large number of
cancer genes are involved. However, only a few of the genes are stage and rate limiting,
leading to a finite number of stages in the multi-stage model of carcinogenesis (Renan,
1993). The age-dependent cancer incidence data for many human cancers imply four to
seven rate-limiting stages from normal stem cells to malignant cancer tumors in most of
human cancers (Renan, 1993). These stages are reflected by observable pathological
lesions and the transition from one stage to the next higher stage may involve several
genetic changes and/or epigenetic changes.
In this section, we gave brief summary of cancer genetics, and some well-recognized
carcinogenesis pathways, such as TGF-β pathway, p53 pathway, and so on.
Usually, three types of genes contribute to cancer phenotype: oncogenes (dominant
cancer genes), suppressor genes (recessive genes) and mis-match repair genes (MMR).
Cancer can be initiated either by the activation of an oncogene, or by inactivating or
silencing a suppressor gene, or a MMR gene.
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If an oncogene is mutated or expressed at high levels, normal growth of a normal
cell is unleashed, leading to continuous proliferating. Most oncogenes interact with many
other genes to promote proliferation or abrogate differentiation and inhibition effects of
many other protection devises.
Tumor suppressor gene is a gene whose action is required for normal development.
When this gene is mutated or inactivated, the cell can progress to cancer, usually by
combination with other genetic changes. Because tumor suppressor genes play more
active roles in cell cycle, for example, tumor suppressor genes either have a dampening
or repressive effect on the regulation of the cell cycle (by controlling the gap stage (G1
and G2)) or promote apoptosis, or control the activation of an oncogene. Stage and rate
limiting genes are usually tumor suppressor genes (Osada & Takahashi, 2002; Weinberg,
2007).
Mismatch repair (MMR) genes are actually tumor suppressor genes but with special
functions that they recognize and repair erroneous insertion, deletion and misincorporation of base that arise during DNA replication and recombination, as well as
repairing some forms of DNA damage. Mutation or deletion of MMR genes lead to
microsatellite repeats and create a mutator phenotype, resulting in genetic instability and
increasing mutation rates of many relevant cancer genes.
Carcinogenesis pathway is usually represented by rate-limiting genes and their order.
It has been observed that the same type of cancer may be developed through more than
one pathway. For example, lung cancer may involve as many as 4 pathways, such as
Wnt, Akt, Hedgedog, and p53 pathways. Similarly, colon cancer is also developed
through many pathways, TGF-β, ras, MAPK, PI3k-Akt and p53 pathways. Because
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different pathway function differently, some pathways may sequentially appear in the
cancer development, for example, p53 pathway always appear at the last stage of cancer
development since mutation of p53 will arrogate apoptosis and lead cells to unregulated
proliferation, while Wnt pathway usually appears in cancer early development because
several proteins involved in this pathway have been associated with the ability of the cell
surface Wnt-activated Wnt receptor complex to bind axin and disassemble the
axin/GSK3 complex, and lead to transcript some oncogenes (Nusse, 2005).
To date, more than 40 pathways have been identified, and more will be discovered
in the future. We gave brief summary of several pathways which are related to cancer
development.

Figure 3. Wnt/β-Catenin Pathway
(Copyright Reserved by “Cell Signaling Technology”)
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Wnt/β-Catenin Pathway
As shown in Figure 3, the Wnt is a secreted glycoprotein that binds to Frizzled
receptors, which triggers a cascade resulting in displacement of the multifunctional
kinase GSK-3β from the APC/Axin/GSK-3β-complex. In the presence of Wnt binding
(On-state), Dishevelled (Dsh) is activated, seemingly at least in part by phosphorylation,
which in turn recruits GSK-3β away from the degradation complex. This allows for
stabilization of β-catenin levels, nuclear import and recruitment to the LEF/TCF DNAbinding factors where it acts as an activator for transcription by displacement of
Groucho-HDAC co-repressors. Importantly, some human cancers harbor point-mutations
in β-catenin leading to its deregulated stabilization, and APC as well as axin mutations
have also been documented, underscoring the involvement of abnormal activation of this
pathway in human tumors. During development the Wnt/β-catenin pathway integrates
signals from many other pathways including FGF, TGF-β and BMP in many different
cell-types and tissues (Bienz, 2000; Gordon & Nusse, 2006; Willert & Jones, 2006).
TGF-β Pathway
As shown in Figure 4, transforming growth factor-β (TGF-β) signaling plays a
critical role in the regulation of cell growth, differentiation, and development in a wide
range of biological systems. In general, signaling is initiated with ligand-induced
oligomerization of serine/threonine receptor kinases and phosphorylation of the
cytoplasmic signaling molecules Smad2 and Smad3 for the TGF-β pathway, or
Smad1/5/8 for the bone morphogenetic protein (BMP) pathway. Phosphorylation of
Smads by activated receptors results in their partnering with the common signaling
transducer Smad4, and translocation to the nucleus. Activated Smads regulate diverse
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biological effects by partnering with transcription factors resulting in cell-state specific
modulation of transcription. TGF-β signaling is also documented to affect Smadindependent pathways, including Erk, SAPK/JNK and p38 MAPK pathways. Activation
of Smad-independent pathways through TGF-β signaling is also common. Rho GTPase
(RhoA) activates downstream target proteins, such as mDia and ROCK, to prompt
rearrangement of the cytoskeletal elements associated with cell spreading, cell growth
regulation, and cytokinesis (Herpin & Cunningham, 2007; Kitisin et al., 2007; Schmierer
& Hill, 2007).
Akt Pathway

Figure 4. TGF-β Pathway
(Copyright Reserved by “Cell Signaling Technology”)
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The Akt (also known as protein kinase B or PKB) has become a major focus of
attention because of its critical regulatory role in diverse cellular processes, including
cancer progression and insulin metabolism. As shown in Figure 5, the Akt cascade is

Figure 5. Akt Pathway
(Copyright reserved by “Cell Signaling Technology”)

activated by receptor tyrosine kinases, integrins, B and T cell receptors, cytokine
receptors, G-protein coupled receptors, and other stimuli. The three Akt isoforms (Akt1,
Akt2, and Akt3) mediate many of the downstream events regulated by PI3K. For
example, Akt is a major regulator of insulin signaling and glucose metabolism, with
genetic studies in mice revealing a central role for Akt2 in these processes. Akt regulates
cell growth through its effects on the mTOR and p70 S6 kinase pathways, as well as cell
cycle and cell proliferation through its direct action on the CDK inhibitors p21 and p27,
and its indirect effect on the levels of cyclin D1 and p53. Akt is a major mediator of cell
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survival through direct inhibition of pro-apoptotic signals such as Bad and the Forkhead
family of transcription factors. Recently, Akt has been demonstrated to interact with
Smad molecules to regulate TGFβ signaling (Bhaskar & Hay, 2007; Brugge, Hung, &
Mills, 2007; Carnero, Blanco-Aparicio, Renner, Link, & Leal, 2008).
p53 Pathway
As shown in Figure 6, p53 is a tumor suppressor protein that regulates the expression
of a wide variety of genes involved in Apoptosis, Growth arrest, Inhibition of cell cycle
progression, Differentiation and accelerated DNA repair or Senescence in response to
genotoxic or cellular Stress. When the cell is confronted with stress like DNA damage,
hypoxia, cytokines, metabolic changes and viral infection, p53 is activated (Francoz et
al., 2006; Hanazono et al., 2006). In addition, p53 can transcriptionally activate PTEN
(Phosphatase and Tensin Homolog), which may further inhibit Akt activity. Therefore,
inhibition of Akt by the inhibitors may trigger a positive feedback with perhaps
additional anti-tumor effects.
Cell cycle inhibition takes place when there is a block in cell-cycle division. p53
does this by stimulating the expression of p21/WAF1/CIP1 (Cyclin Dependent Kinase
Inhibitor-p21). This protein is an inhibitor of CDKs (Cyclin-Dependent Kinases) that
regulate the cell cycle via perturbation of their partner cyclin. Since p21/WAF1/CIP1
inhibits CDKs it results in inhibition of both G1-to-S and G2-to-mitosis transitions by
causing hypophosphorylation of Rb (Retinoblastoma) and preventing the release of E2F.
Additionally p53 can stimulate 14-3-3, a protein that sequesters Cyclin B1-CDK1
complexes out of the nucleus. This results in a G2 block. Activated p53 may also initiate
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apoptosis and stop cell proliferation (Akhtar, Geng, Klocke, & Roth, 2006; Zheng, Ma,
Zhu, Zhang, & Tong, 2006).

Figure 6. p53 Pathway
(Copyright Reserved by Biocarta)

Mutations in p53 are associated with genomic instability and increased susceptibility
to cancer. It is the most frequently mutated protein in all cancer with an estimated 60% of
all cancers having mutated forms that affect its growth suppressing activities. However
some common tumors have a higher incidence such that 90% of cervical and 70% of
colorectal are found to have p53 mutations. The p53 protein can be inactivated in several
ways, including inherited mutations that result in a higher incidence of certain familial
cancers such as Li-Fraumeni syndrome (Francoz et al., 2006; Gomes & Andrade, 2006;
Jiang et al., 2006).
Parameters Estimation
We have shown in section 1.2 that a state space model for a complex system usually
contains many parameters, depending on the number of pathways and the number of
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stage in each pathway. In order to estimate the parameters simultaneously, Tan and Ye
(2000) have developed general Bayesian procedures based on state space model, while
the state variables are estimated by multi-level Gibbs sampling and weighted bootstrap
procedures. In this section, we briefly introduced these procedures.
Information coming from three sources makes these procedures possible and
reliable:
Prior information comes from previous studies or experiences, which give
reasonable range or distribution of parameters.
Biological mechanisms, such as pathways we discussed in previous section,
provide the information for constructing stochastic differential equations and conditional
distribution.
Observation is represented by statistical model, which connects the biological system
by incidence function, and also controls the randomness of observation.
We used two-pathway model described in section 1.1 as an example to illustrate the
procedures. Let X be state variables {N(t), I1(t), I2(t), T(t)}, Θ the set of all unknown
parameters {α1, α2, ω1, β1, b1, d1, b2, d2} and Y the observed data, say cancer incidence
for each age group. Let P(θ) be the prior distribution of the parameters, constructed by
previous studies. If the prior information is vague, then a uniform or non-informative
prior is applied. Let P(X|Θ) be the conditional probability density of X given the
parameters Θ and P(Y|X, Θ) the conditional probability density of Y given X and Θ. P(X
|Θ) is derived from the stochastic system model and P(Y|X,Θ) is derived from the
observation model and is usually taken as likelihood function. By combining three
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distributions, we can obtain the joint distribution of {X, Y, Θ}: P(X, Y, Θ) = P(Θ) P(X |Θ)
P(Y |X, Θ). Then conditional distributions P(X |Y, Θ) and P(Θ| X, Y) are derived by:
| ,

|

| ,

| ,
|

| ,

Using these conditional probability distributions, one can estimate the unknown
parameters and predict the state variables by using the multi-level Gibbs sampling
procedures (Liu & Chen 1998; Shephard, 1994, Tan, Zhang, Chen, & Zhu, 2008a; Tan,
Zhang, Chen, & Zhu, 2008b). The algorithm is as following:
(1) Given Y and initial value of Θ(0), generated X(*) from P(X|Y, Θ(0)).
(2) Generate Θ(*) from P(Θ| X(*), Y)
(3) Back to step (1) to generate new X(*) from updated P(X | Y, Θ(*))
(4) Repeat (1)-(3) till convergence.
The convergence of the above algorithm has been proved by Tan (2002). At
convergence, one can generate a large set of X from P(X | Y), independent on Θ, and
generate a large set of Θ from posterior marginal distribution of P(Θ| Y), independent on
X. Then we can use the sample means of X and Θ as estimates of X and Θ respectively,
and use the sample variances as variances of the estimates. Alternatively, one can use
also Efron’s bootstrap method (Efron, 1982) to estimate the standard errors of estimates.
To implement the above procedures, one difficulty is that P(X | Y, Θ) is hard to
derive in practice. In order to generate X from conditional distribution of P(X | Y, Θ), Tan
and Chen (1998) have developed an indirect method based on the weighted bootstrap
method (Smith & Gelfand, 1992). The algorithm used in weighted bootstrap method
follows:
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(1) Given Θ(0) and X(l) (0 ≤ l ≤ j), generate a large number of random sample of size
1 |

N from
1 ,…,

{
(2) Compute

(from the stochastic system model), denoted them by
1 }.
1 |

,

0,1, … , ,

1 ,

and p

Ω /

∑N Ω for k = 1, …, N.
(3) Construct a population π with element (E1,…, EN) and with P(Ek) = p . Draw an
element randomly from π, if the outcome is Ek, then X
X j

j

1 is the element

1 from the conditional P(X | Y, Θ).

(4) Repeat (1)-(3) until j = TM, which is largest time point for discrete time in
stochastic system.
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2. STOCHASTIC MODELS OF CARCINOGENESIS FOR INITIATIONPROMOTION BIOASSAY AND APPLICATIONS

Introduction

To assess cancer risk of environmental agents, a common approach is to conduct
initiation-promotion experiments using the mouse skin bioassay system to test if the
agent can initiate cancer and/or promote cancer (Misfeld, 1980; Waters, Sandhu,
Huisingh, Claxton, & Nesnow, 1981). For example, during the 1980’s, the US EPA had
conducted extensive initiation-promotion experiments to test a wide range of
environmental risk agents. These environmental agents include among others,
benzo(a)pyrene, topside coke oven extract, coke oven main extract, Nissan extract,
roofing tar extract, Oldsmobile extract, Mercedes extract, Caterpillar extract, residential
extract, and Mustang extract. For each of these environmental agents, valuable data
concerning the number of papillomas and carcinomas had been generated. Many of these
data were summarized in the paper by Nesnow et al. (1982); to date these useful data
have only been used to construct empirical dose- response curves without any input from
biologically supported model of carcinogenesis. Tan, Chen, and Wang (2001) have used
the average number of papillomas per animal over different time points from Nissan
extract to develop a state space model for the generation of papillomas. In this paper we
will develop a comprehensive stochastic model of carcinogenesis for these experiments.
We will show that even with some summary data as given in Nesnow et al. (1982), by
using these models we will be able to extract extensive information than are possible by
statistical methods.
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In Section 2.2, we will develop a stochastic model for the initiation-promotion
experiments using mouse skin bioassay. In Section 3, we will derive stochastic equations
and probability distributions of state variables in these experiments. Using results from
Section 2.3, in Section 2.4 we will develop statistical models and probability distributions
for data on papillomas and carcinomas from these experiments. In Section 2.5, by using
results from the above sections, we will develop some statistical inference procedures to
estimate unknown genetic parameters, to validate the model and to predict future cases.
In Section 2.6, we will apply the models and methods of this paper to analyze some
summary data in Nesnow et al. (1982). We will show that even with some summary data
we will be able to derive many useful results and extract some important information
from the system. To further confirm the usefulness of our model and methods, in Section
2.7 we will generate some Monte Carlo data to illustrate the model and methods, will
discuss the usefulness of the model and methods.
A Stochastic Model for Initiation-Promotion Bioassay
In initiation-promotion bioassay experiments, mouse skin is shaved and is exposed to
a chemical called “Initiator” for a short time period (normally a few days or a week);
immediately following initiation the exposed mice are treated by a chemical called
“Promoter” weekly or twice weekly until sacrifice or termination of experiment. From
studies of molecular biology of skin cancer (DiGiovanni 1992; Hennings et al., 1993;
Missero, D’Errico, Dotto, & Dogliotti, 2002; Weinberg, 2007, pp. 435-439; Yuspa,
1994), carcinogenesis for this bioassay experiment to generate papillomas and
carcinomas can best be described by a multiple pathway model involving a two-stage
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model and an one-stage model; see Remark 1. This is represented schematically in
Figure 7.
In Figure 7, the animal is in stage I1 if the H-ras oncogene in a skin stem cell of the
animal has been mutated (Brown, Buchmann, & Balmain, 1990; Missero et al., 2002;
Weinberg, 2007, P.439). The I1 stage animal is in stage I2 if the p53 gene in an I1 cell of
this animal has been mutated or deleted or inactivated (Missero et al., 2002; Weinberg,
2007; Ruggeri et al., 1991); the animal is in stage I2 immediately after treatment if the
agent can induce mutations of both the H-ras gene and the p53 gene simultaneously.
Thus, an agent is an initiator if the agent can induce H-ras mutation in skin stem cells in
animals and is a strong initiator if it can induce mutation of both the H-ras gene and the

Figure 7. Multiple-pathway for Initiation and Promotion
p53 gene at the same time in some skin stem cells of mice. Promoters such as TPA (12-0
tetradecanoylphorbol-13-acetate) cannot induce genetic changes but only promote cell
proliferation of initiated cells (Hennings et al., 1993; Weinberg, 2007). Karin, Liu, and
Zandi (1997), Saez et al. (1995), and Weinberg (2007, P.439) have shown that promoters
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such as TPA act synergistically with the H-ras gene protein to activate kinase Cα (PKCα) which in turn activates the NK- B, the AP-1 (heterodimer of c-jun and c-fos
oncogenes) and the MAPK signal pathways to drive cell proliferation; Missero, Ramon,
Cajal, and Dotto (1991) and Missero et al. (2002) have also noticed that promoters may
facilitate cell proliferation of I1 cells by inhibiting TGF-β (Transforming Growth Factor
β) activities.
In the model in Figure 7, the Ir (r = 1, 2) cells are subjected to stochastic birth and
death and each cell proceeds forward independently of other cells. Further, papillomas
develop from primary I1 cells through clonal expansion (i.e., stochastic birth-death) of
these cells, where primary I1 cells are I1 cells generated directly by normal stem cells.
Similarly, carcinomas develop from primary I2 cells by clonal expansion (stochastic birth
and death) of these cells, where primary I2 cells are I2 cells generated directly by mutation
from I1 cells. From this it is clear that the two-stage model in Figure 7 is not the classical
MVK two-stage model because the MVK model assumes that I2 cells grow
instantaneously into carcinomas as soon as they are generated ignoring completely the
stochastic birth and death of I2 cells; see Tan (1991, Chapter 3).
Let t0 be the time to start the experiment and

the time to end initiation. For the

model in Figure 7, the response variables (state variables) are the number Ir(t) (r = 1, 2)
of Ir cells at time t (t ≥ t0), the number YP (t) of papillomas at time t and the number YC(t)
of carcinomas at time t.
In the next section, we will derive probability distributions of these variables under
different bioassay experiments.
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Remark 2.1. Because the promoter cannot induce genetic changes, the data in Table
2 implied that carcinomas could only be derived from I2 cells generated by the initiator
during the short initiation period.
The Stochastic Equations and Probability Distribution of State Variables in
Initiation-Promotion Experiments
Let

= {Ir(t), r = 1, 2}. To derive probability distribution of the state variables,

observe that {X(t), t ≥ t0} is a two-dimensional Markov process although YP(t) and YC(t)
may not be Markov. For simplicity, notice further that we can make the following two
assumptions: (a) Since the number of normal stem cells is very large (i.e., 108 ~ 109) and
the size of organ in adult mice is stable, it is reasonable to assume that the number N(t) of
normal stem cells at time t is a deterministic function of t and is a constant (i.e., N(t) =
N0). (b) Because the spontaneous mutation rates from N→ Ir (r = 1, 2) and from I1→I2 are
very small, in practice one can ignore spontaneous mutations from N → Ir (r = 1, 2) and
from I1 → I2; thus we assume that N → Ir (r = 1, 2) mutations can only be generated by
initiators and I1 → I2 can only be generated by initiators or mutagen (not by promoters;
see Hennings et al., 1983).
Experiments in Which the Agent Is Used as an Initiator
In these experiments, similar animals are treated by the testing agent at time t0 for a
very short period with k different dose levels (ui, i = 1, . . . ,k); then the treated animals
are promoted by a well-known promoter such as TPA with fixed dose level weekly or
twice weekly until sacrifice or the end of experiment. Let sj (j = 1, . . . ,m) be the time to
start the j −th round of promotion with promotion period sj+1 −sj = 7 days when
promotion is applied weekly or 3 and half days when promotion is applied twice weekly.
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If the agent is an initiator, it would induce mutation of the H-ras oncogene in some
normal skin stem cells in mice to generate I1 cells during the initiation period (t0,

] and

hence papillomas at later times. If the agent is a strong carcinogen, with positive
probability it may also induce mutations of both the H-ras gene and the p53 gene
simultaneously in some skin stem cells in animals to generate I2 cells during (t0,

] and

hence carcinomas at later times; see data Table 2 where both papillomas and carcinomas
are generated by the initiator.
Let αr(i) > 0 (r = 1, 2) be the mutation rate from N → Ir induced by the agent with
dose level ui during the initiation period, where (α1(i) > α2(i) > 0). Let Xr(i) (r = 1, 2) be
the number of Ir cells generated during (t0,

] in the animal treated by the agent with

dose level ui. Because the αr(i) (r = 1, 2)’s are very small, the Xr(i) (r = 1, 2, i = 1, . . . ,k)
are distributed as Poisson random variables with mean λr(i) respectively, where λr(i) =
αr(i)N0 (r = 1, 2, i = 1, . . . ,k). That is,
Xr(i) ~ Poisson{λr(i)}.

(2.1)

The Stochastic Equations and Probability Distribution of State Variables
Let {Br(j), Dr(j)} (r = 1, 2) denote the number of birth and the number of death of the
Ir cells respectively in the animal during (sj, sj+1] (j = 1, . . . ,m). Because the promoter
would not induce genetic changes but only increase the proliferation rates of Ir cells, by
the conservation law we have the following stochastic equations for Ir(t) (r = 1, 2):
Ir(sj+1) = Ir(sj) + Br(j) − Dr(j), j = 1, . . . ,m,
Ir(t) = Ir(

) = Xr(i) for

(2.2)

≤ t ≤ s1, i = 1, . . . ,k.

In the above equations, notice that the {Br(j), Dr(j)} are independent of the agents
and hence independent of the dose levels ui of the agent. Notice also that only the
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initiated number of Ir cells at

is dependent on the agent and hence the dose levels of

the agent.
To derive probability distributions of the Ir(t) (r = 1, 2), let br(j) and dr(j) denote the
probability of birth and the probability of death of the Ir cells during the time period (sj,
sj+1] respectively. (Because sj+1−sj is a constant, one may assume (br(j) = br, dr(j) = dr).)
These probabilities depend only on the promoter and hence are independent of the agent
and the dose level of the agent. It is shown in Tan (2002, Chapter 8) that the conditional
probability distribution of {Br(j), Dr(j)} given Ir(sj) is multinomial with parameters {Ir(sj),
br, dr}. That is,
{Br(j),Dr(j)}| Ir(sj ) ~ Multinomial{Ir(sj); br, dr}, r = 1, 2, j = 1, . . . ,m.

(2.3)

Let f(x; N, p) denote the density at x of X ~ Binomial{N, p}. Using equation (2.2) and
the above conditional probability distribution of {Br(j), Dr(j)} given Ir(sj), we obtain for (r
= 1, 2, j = 1, . . . ,m, i = 1, . . . ,k):
P{Ir(sj+1) = n2|Ir(sj) = n1} = ∑
× f{n1 − n2 + u; n1 − u,

(u; n1, br)δ(n1 − n2 + u)
},

(2.4)

where Ir(s1) = Xr(i), r = 1, 2 under treatment with dose level ui and where δ(n1−n2+u)
= 1 if n1 − n2 + u ≥ 0 and = 0 if n1 − n2 +u < 0.
Let h(x; λr(i)) denote the density at x of the Poisson distribution Xr(i) ~
Poisson{λr(i)}. Then, for r = 1, 2 and i = 1, . . . ,k, the probability P{Ir(s2) = n; i} of Ir(s2)
= n under treatment with dose level ui is:
P{Ir(s2) = n; i} =∑∞
−v,

{u; λr(i)}∑

(v; u, br)δ(u − n + v) × f(u − n + v; u

).

(2.5)
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The Probability Distribution of the Number of Papillomas
To derive probability distribution of the number of papillomas, observe that
papillomas are produced by clonal expansion (i.e., stochastic birth and death process) of
I1 cells generated by the initiator during the initiation period and that the I1 cells can only
proliferate under promotion by the promoter after time s1. Let PI (s1, t) = PI (t − s1) denote
the probability that a primary I1 cell at s1 develops into a detectable papillomas by time t
(t ≥ s1 > t

). Then, as proved in Tan (2002, Chapter 8),

PI(s1, t) = PI(t − s1) =

×

where γ1 = b1 − d1, θI =

,

(2.6)

and where NI is the number of I1 cells in the papillomas

for the papillomas to be detectable.
Let YP (t; i) be the total number of papillomas by time t derived from the X1(i) I1 cells
which are generated by the initiator with dose level ui during (t0,

]. Then

YP (t; i)| X1(i) ~ Binomial{X1(i), PI (t − s1)}. Since X1(i) ~ Poisson{λ1(i)}, so,
P(YP (t; i) = j) =∑∞
=∑∞
=

(u; λ1(i))f(j; u, PI (t − s1))
[1 − PI (t − )

!

[λ1(i)PI (t − s1) ∑∞

!

=

!

!

{λ1(i)[1 − PI (t − s1)]

[λ1(i)PI (t − s1)
.

!

(2.7)

It follows that,
YP (t; i) ~ Poisson{λ1(i)PI(t −

)}.

(2.8)
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The Probability Distribution of Carcinomas
To derive probability distribution of the number of carcinomas, observe that
carcinomas are produced by clonal expansion (i.e., stochastic birth and death process) of
I2 cells generated by the initiator. Let PC(s1, t) denote the probability that an I2 cell at s1
develops into a detectable carcinomas by time t (t ≥ s1 >

). Then, as shown in Tan

(2002, Chapter 8),
PC(s1, t) = PC(t − s1) =
where γ2 = b2 − d2, θC =

×

,

(2.9)

and where NC is the number of I2 cells in the carcinoma for the

carcinoma to be detectable.
Let YC(t; i) be the total number of carcinomas by time t produced by the X2(i), I2 cells
which are generated by the initiator with dose level ui during (t0,

]. Then

YC(t; i)| X2(i) ~ Binomial{X2(i), PC(t − s1)}. Since X2(i) ~ Poisson{λ2(i)}, so,
YC(t; i) ~ Poisson{λ2(i)PC(t − s1)}, i = 1, . . . ,k.

(2.10)

Experiments in Which the Agent Is Used as a Promoter
When the agent is an initiator, the next step is to test if the agent is also a promoter.
In the initiation-promotion experiment, one then uses a well-known initiator such as
B(a)P (benzo[a]pyrene) as the initiator with fixed dose level but use the testing agent as
the promoter with k dose levels ui (i = 1, . . . ,k). Because the I1 cells can proliferate only
under promotion, if the agent is not a promoter, the number of I1 cells are very small and
hence papillomas and carcinomas would not be generated. On the other hand, if the agent
is a promoter, then, papillomas and possibly carcinomas will be generated at latter times.
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In this experiment, when both the initiator and the testing agent (i.e., the promoter)
are strong carcinogens, the Ir (r = 1, 2) cells are generated not only by the initiator during
the initiation period (t0,

], but also by the testing agent during promotion periods (sj,

] (j = 1, . . . ,m).
The Stochastic Equations and Probability Distribution of State Variables
Let

(r = 1, 2) denote the number of Ir cells generated by the initiator during the

initiation period and Xr(i, j) (r = 1, 2, i = 1, . . . ,k, j = 1, . . . ,m) the number of Ir cells
generated by the testing agent with dose level ui during the promotion period (sj, sj+1]. Let
νr (r = 1, 2) be the mutation rate of N → Ir by the initiator. (νr ≠ αr because the initiator
used is not the testing agent.) Then, as in Section (2.3.1), we have for (r = 1, 2):
~ Poisson{ωr}, with ωr =

,

Xr(i, j) ~ Poisson{λr(i)}, independently for i = 1, . . . ,k, j = 1, . . . ,m.

(2.11)

To derive stochastic equations for the state variables, let {Br(i, j), Dr(i, j)} (r = 1, 2, j
= 1, . . . ,m, i = 1, . . . ,k) denote the number of birth and the number of death of the Ir cells
respectively in the animal during (sj−1, sj ] under promotion by the agent with dose level
ui. Let M1(i, j) (j = 1, . . . ,m) denote the number of mutation from I1 → I2 in the animal
during (sj, sj+1] under promotion by the agent with dose level ui. By the conservation law
we have the following stochastic equations for Ir(t) (r = 1, 2):
I1(sj+1) = I1(sj) + X1(i, j) + B1(i, j) − D1(i, j), j = 1, . . . ,m,
i = 1, . . . ,k with I1(t) = I1(

)=

for

≤t≤

;

(2.12)

I2(sj+1) = I2(sj) +M1(i, j) + X2(i, j) + B2(i, j) − D2(i, j), j = 1, . . . ,m,
i = 1, . . . ,k, with I2(t) = I2(

)=

for
43

≤t≤

.

(2.13)

To derive probability distribution of the state variables, let br(j; i) = br(i) and dr(j; i) =
dr(i) denote the probability of birth and the probability of death of the Ir (r = 1, 2) cells
during the interval (sj,

] under promotion with dose level ui respectively. Let β1(j; i) =

β1(i) be the probability of mutation from I1 → I2 during the promotion period (sj,

]

under promotion by the agent with dose level ui. Then as in the previous section, we
have:
{Br(i, j), Dr(i, j)}| Ir(sj) ~ Multinomial{Ir(sj), br(i), dr(i)}, independently for r = 1, 2, j
= 1, . . . ,m, i = 1, . . . ,k;

(2.14)

M1(i, j)| I1(sj) ~Poisson{I1(sj)β1(i)}, independent of Br(i, j), Dr(i, j), Xr(i, j),
2, j = 1, . . . ,m, i = . . . , k.

, r = 1,
(2.15)

Let g(x, y; N, p, q) denote the density at (x, y) of a multinomial distribution (X, Y) ~
Multinomial{N; p, q}. Using equations (2.12)-(2.13) and the probability distributions in
equations (2.14)-(2.15), we obtain:
) = n1 | I1(sj) = r1} = ∑

P{I1(
× h{

−

−

+

;

∑

{

,

;

,

(i),

;

,

(i),

(i)}

(i)}

(2.16)

P{I2(sj+1) = n2 | I1(sj) = r1, I2(sj) = r2} = ∑
× g{

,

∑

∑

{l;

(i)}

;

(i)}

×

(2.17)

where δ(x) = 1 if x ≥ 0 and = 0 if x < 0.
To derive probability distributions of papillomas and carcinomas, notice that
papillomas are generated from
from

and X1(i, j) cells whereas carcinomas are generated

cells, X2(i, j) cells and M1(i, j) cells.
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The Probability Distribution of Papillomas
To derive probability distribution of the number of papillomas, observe that each
papilloma is derived by clonal expansion (i.e., stochastic birth and death process) from a
single primary I1 cell;

are primary I1 cells generated by the initiator during the

initiation period and X1(i, j) are primary I1 cells generated by the testing agent during
promotion periods (sj,
by time t derived from

] (j = 1, . . . ,m). Let

(t; i) denote the number of papillomas

cells and YP (t; i, j) the number of papillomas by time t

derived from X1(i, j) cells. Then these variables (i.e., {

(t; i), YP (t; i, j), i = 1, . . . ,k, j

= 1, . . . ,m}) are independently distributed of one another. As in the previous section, the
probability distributions of these variables are:
(t; i) ~ Poisson {ω1 PI (t − s1; i)},
YP (t; i, j) ~ Poisson {λ1(i) PI(t −

; i)},

independently for i = 1, . . . ,k, j = 1, . . . ,m,

(2.18)

where
PI(

; i) =

,

×

where γ1(i) = b1(i) − d1(i), θI(i) =

, i = 1, . . . ,k.

(2.19)

Let YP (t; i) be the total number of papillomas by time t generated by the initiator and
by the agent with dose level ui. Then YP (t; i) =
YP(t; i) is distributed as Poisson with mean

(t; i)+∑

(t; i, j). It follows that

(t; i) = ω1PI (t − ; i) +∑

1(i)PI

(t –sj+1;

i). That is,
YP (t; i) ~ Poisson{

(t; i)}.

(2.20)
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The Probability Distribution of Carcinomas
To derive probability distribution of the number of carcinomas, observe that each
carcinoma is derived by clonal expansion from a single primary I2 cell. Hence,
carcinomas are derived by clonal expansion from
cells as these cells are primary I2 cells. Let
time t derived from
X2(i, j) cells and

cells, X2(i, j) cells and from M1(i, j)

(t; i) denote the number of carcinomas by

cells, YC(t; i, j) the number of carcinomas by time t derived from
(t; i, j) the number of carcinomas by time t derived from M1(i, j)

cells. Then the variables {

(t; i), YC(t; i, j),

(t; i, j), i = 1, . . . ,k, j = 1, . . . ,n} are

independently distributed of one another. As in the previous section, the probability
distributions of these variables are:
(t; i) ~ Poisson {ω2PC(t − s1; i)},
YC(t; i, j) ~ Poisson { 2(i)PC(t −

; i)},

independently for i = 1, . . . ,k, j = 1, . . . ,m,
where
PC(t − sj ; i) =
where

×

(i) = b2(i) − d2(i), θC(i) =

(2.21)

, i = 1, . . . ,k.

To derive the probability distribution of
distribution of

,

(t; i, j), observe that the conditional

(t; i, j) given M1(i, j) is binomial with parameters {M1(i, j), PC(t −

i)} and the conditional distribution of M1(i, j) given I1(sj) cells is Poisson with mean
I1(sj)β1(i). Hence the conditional distribution of
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(t; i, j) given I1(sj) is Poisson with

;

mean I1(sj)β1(i)PC(t −

; i). It follows that to the order of o(β1(i)), the distribution of

(t; i, j) is Poisson with mean E[I1(sj)]β1(i)PC(t −

; i).

Let YC(t; i) be the total number of carcinomas by time t generated by the initiator and
by the agent with dose level ui. Then YC(t; i) =

(t; i)+∑

J

YC(t; i, j)+YC (t; i, j)]. It

follows that to the order of o(β1(i)), YC(t; i) is distributed as Poisson with mean
ψC(t; i) = ω2PC(t − s1; i) + ∑

2(i)

+ E(I1(sj))β1(i)]PC(t −

; i). That is,

YC(t; i) ~ Poisson{ψC(t; i)}.

(2.22)

Experiments in Which the Agent Is Used as a Complete Carcinogen
The testing agent is a complete carcinogen if it is both an initiator and a promoter.
To test if the environmental agent is a complete carcinogen, the agent is used both as an
initiator and a promoter with dose levels ui(i = 1, . . . ,k). Thus, the experiment is similar
to the experiment in Section 2.3.2 except that the initiator is now the testing agent with
dose level ui (i = 1, . . . ,k). In these experiments, if papillomas are not generated, then
either the agent is not an initiator, or the agent is not a promoter; the agent is a complete
carcinogen if papillomas are generated in the experiment.
Stochastic Equations and Probability Distribution of the State Variables
Let Xr(i; 0) (r = 1, 2, i = 1, . . . ,k) be the Ir cells generated by the agent with dose
level ui during the initiation period. Because the length of initiation period is very short
and is approximately equal to the promotion period

− sj , Xr(i; 0) ~ Poisson{λr(i)}

independently of Xr(i; j) (j = 1, . . . ,m), where Xr(i; j) is defined in Section 2.3.2.
Obviously, except with Ir(t) = Xr(i; 0) (r = 1, 2) for

≤ t ≤ s1 under the initiator with

dose level ui, the stochastic equations for Ir(t) are exactly the same as given by equations
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(2.12)- (2.13) respectively. Similarly the conditional probability distributions of {Br(i;
j),Dr(i; j)} given Ir(sj) and the conditional probability distribution of M1(i, j) given I1(sj)
are given by equations (2.14)-(2.15) respectively. It follows that the conditional
probability distribution of (

) given (sj) are given by equations (2.16)-(2.17)

respectively.
The Probability Distributions of Papillomas and Carcinomas
Let YP (t; i, 0) (YC(t; i, 0)) denote the number of papillomas (carcinomas) by time t
generated by the initiator with dose level ui during the initiation period respectively.
Then, with notations from Section 2.3.2, YP(t; i) = ∑
i, j)+

(t; i, j) and YC(t; i) = ∑

YC(t;

(t; i, j)]. Further,
YP(t; i, j) ~ Poisson {λ1(i)PI (t − s1; i)}, j = 0, 1, . . . ,m

(2.23)

YC(t; i, j) ~ Poisson{λ2(i)PC(t −

(2.24)

; i)}, j = 0, 1, . . . ,m;

and to the order of o(β1(i)),
(t; i, j) ~ Poisson{E[I1(sj)]β1(i)PC(t −

; i)}, j = 1, . . . ,m.

Hence,

where

YP (t; i) ~ Poisson{ηP(t; i)}.

(2.25)

YC(t; i) ~ Poisson{ηC(t; i)},

(2.26)

(t; i) = ∑

(i)PI(t −

(t; i) = λ2(i)PC(t − s1; i) +∑

; i) and
λ2(i) + E(I1(sj))β1(i)]PC(t −

; i).

Statistical Models and Probability Distributions
In initiation-promotion experiments, similar mice are randomized into k groups. In
the i-th group, ni (i = 1, . . . ,k) animals are treated by the testing agent with dose level ui;
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among these ni animals, ni(l) animals are sacrificed at time tl when autopsies are
performed over these sacrificed animals and the numbers of papillomas and carcinomas
are counted. The observed data available are the number mP(i) of animals with papillomas
among the ni(l) animals sacrificed at time tl in the i−th treatment group, the average
number YP(tl, i) of papillomas per animal in the i−th treatment group over the ni(l)
animals sacrificed at time tl, the number

(i) of animals with carcinomas in the i−th

treatment group among the ni(l) animals sacrificed at time tl and the average number
YC(tl, i) of carcinomas per animal in the i−th treatment group among the ni(l) animals
sacrificed at time tl. Given in Tables 2-4 are these observed numbers in percentages with
tl equal to six months or one year. To develop statistical models for these observed data,
in what follows we let YP (v; tl, i) be the number of papillomas by time tl in the v-th
mouse in the i − th treatment group among the ni(l) mice sacrificed at time tl; similarly,
we let YC(v; tl, i) be the number of carcinomas by time tl in the v-th mouse in the i – th
treatment group among the ni(l) mice sacrificed at time tl.
Using results from Section 2.3, in this section we will develop statistical models for
these observed variables and derive probability distributions generating these observed
data under different initiation-promotion bioassay experiments.
Experiments in Which the Testing Agent Is Used as an Initiator
From results in Section (2.3.1.2) and equation (2.8), the probability that the animal in
the i−th treatment group would develop at least one detectable papillomas by time tl is
(tl; i) = 1 − exp{−λ1(i)PI (tl − s1)}.
It follows that
(i) | ni(l) ~ Binomial{ni(l),

(tl; i)}, independently for i = 1, . . . ,k.
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(2.27)

The deviance

(m; i) of the density in (2.27) is

(m; i) = 2{

(i) −

(i) log [

(tl; i)] − [ni(l) − mP(i)] log[1 − Q P (tl; i)]},
(2.28)

where AP(i) =

(i) log[

(i)] + [ni(l) −

(i)] log[ni(l) −

(i)] − ni(l) log[ni(l)].

By equation (2.8) in Section (3.1.2), we have also that
YP(v; tl, i) ~ Poisson{λ1(i)PI(tl − s1)}, independently for v = 1, . . . ,ni(l), i = 1, . . . ,k.
(2.29)
It follows that
YP(tl, i) =

∑

(v; tl, i) = λ1(i)PI(tl − s1) +

(i), independently for i = 1, . . .

,k.

(2.30)
In the above equation,

(i) has expected value 0 and variance

λ1(i)PI(tl − s1).

When ni(l) is not small, by the central limit theorem one may practically assume that
the

(i) are independently distributed as normal random variables.
Using this distribution result, the deviance

(Y ; i) of the density of YP(ti, i) is

(Y ; i) = log{λ1(i)PI (tl − s1)} − log ni(l) +

,
(2.31)

Let

(tl; i) be the probability that the animal in the i−th treatment group would

develop at least one detectable carcinomas by time tl. From results in Section (2.3.1.3)
and equation (2.10), we obtain

(tl; i) = 1 − exp{−λ2(i)PC(tl − s1)} and

mC(i) | ni(l) ~ Binomial{ni(l),
The deviance

(tl; i)}.

(m; i) of the density in (2.32) is
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(2.32)

(m; i) = 2{AC(i) − mP(i) log [

(tl; i)] − [ni(l) − mC(i)] log[1 −

(tl; i)]},

(2.33)
where

(i) =

(i) log[

(i)] + [ (l) −

(i)] log[ (l) −

(i)] − ni(l) log[ni(l)].

Similarly, by equation (2.10) in Section (3.1.3), we have that
YC(v; tl, i) ~ Poisson{λ2(i)PC(tl − s1)}, independently for v = 1, . . . ,ni(l), i = 1, . . . ,k.
(2.34)
It follows that
YC(tl, i) =

∑

(v; tl, i) = λ1(i)PI(tl − s1) +

(i), independently for i = 1, . . .

,k

(2.35)
By the central limit theorem, the eC (i) are distributed independently as normal

variables with expected value 0 and variances
Using this distribution result, the deviance Dev

approximately.
(Y; i) of the density of YC(ti, i) is

(Y ; i) = log{λ2(i)PC(tl − s1)} − log ni(l) +

× (YC(tl, i) − λ2(i)PC(tl −

s1 ) .

(2.36)

Experiments in Which the Testing Agent Is Used as a Promoter
As in Section (2.3.2), assume that a well-known chemical (e.g., B(a)P) with certain
fixed dose level is used as an initiator but the testing agent is used as a promoter over k
dose levels (ui, i = 1, . . . ,k).
Let Q P (tl; i) be the probability that the animal in the i−th treatment group would
develop at least one detectable papillomas by time tl; and Q
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(tl; i) the probability that

the animal in the i−th treatment group would develop at least one detectable carcinomas
by time tl. Then, we have:
(tl; i) = 1− exp{−

(tl; i)}, with

(tl; i) = 1− exp{−

(tl; i)}, with

(t; i)=

PI t

s ; i +∑

P t

s ; i +∑

(i)PI (tl − sj+1;

i);

E(I1(sj))β1(i)]PC(tl −

(t; i)=

λ2(i) +

; i),

where PI(tl − sj ; i) and PC(tl − sj ; i) are given in equations (2.18) and (2.22) respectively.
It follows that
(i)|ni(l) ~ Binomial{ni(l),

(tl; i)},

(2.37)

(i)|ni(l) ~ Binomial{ni(l),

(tl; i)},

(2.38)

independently for i = 1, . . . ,k.
The deviance

(m; i) of the density in (2.37) and the deviance

(m; i) of

the density in (2.38) are given respectively by:
(m; i) = 2{AP(i) −

(i) log[

(tl; i)] − [ni(l) −

(i)] log[1 −

(tl; i)]},
(2.39)

(m; i) = 2{AC(i) −

(i) log[

(tl; i)] − [ni(l) −

(i)] log[1 −

(tl; i)]}.
(2.40)

Similarly, from equations (2.18) and (2.22) in Section (2.3.2),
YP (v; tl, i) ~ Poisson{

(tl; i))}; YC(v; tl, i) ~ Poisson{

(tl; i))}, independently for v

= 1, . . . ,ni(l), i = 1, . . . ,k.
It follows that
YP (tl, i) =

∑

(v; tl, i) =

(tl; i) +
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(i),

(2.41)

∑

YC(tl, i) =

(v; tl, i) =

(tl; i) +

(i),

(2.42)

independently for i = 1, . . . ,k.
By the central limit theorem, the

(i) and the

distributed with means 0 and variances
The deviance

(i) are approximately normally

(tl; i) and

(tl; i) respectively.

(Y; i) of the density in (2.41) and the deviance

(Y; i) of

the density in (2.42) are given respectively by:
(Y; i) = log{

(tl; i)}− log ni(l) +

(Y; i) = log{

(tl; i)}− log ni(l) +

;

;

× (YP (tl, i) −

(tl; i) .

(2.43)

× (YC(tl, i) −

(tl; i) .

(2.44)

Experiments in Which the Testing Agent Is Used as a Complete Carcinogen
(tl; i) be the probability that the animal in the i−th treatment group would

Let

develop at least one detectable papillomas by time tl; and

(tl; i) the probability that

the animal in the i−th treatment group would develop at least one detectable carcinomas
by time tl. Then, we have:
(tl; i) = 1− exp{−

(tl; i)}, with

(tl; i) = 1− exp{−

(tl; i)}, with

(t; i) =

(i)PC(tl −

; i) + ∑

(t; i) =∑

(tl −

λ2(i) + E(I1(sj ))β1(i)]PC(tl −

; i);

; i),

where PI (tl − sj; i) and PC(tl − sj+1; i) are given in equations (2.18) and (2.21)
respectively.
It follows that
(i) | ni(l) ~ Binomial{ni(l),

(tl; i)};
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(2.45)

(i) | ni(l) ~ Binomial{ni(l),

(tl; i)},

(2.46)

independently for i = 1, . . . ,k.
The deviance

(m; i) of the density in (2.45) and the deviance

(m; i) of

the density in (2.46) are given respectively by:
(m; i) = 2{AP(i) −

(i) log [

(tl; i)] − [ni(l) −

(i)] log [1 −

(tl; i)]},
(2.47)

(m; i) = 2{AC(i) −

(i) log [

(tl; i)] − [ni(l) −

(i)] log [1 −

(tl; i)]}.
(2.48)

Similarly, from equations (2.25) and (2.26) in Section (2.3.2),
YP (v; tl, i) ~ Poisson{

(tl; i))}; YC(v; tl, i) ~ Poisson{ (tl; i))},

independently for v = 1, . . . ,ni(l), i = 1, . . . ,k.
It follows that
YP(tl, i) =

∑

(v; tl, i) =

(tl; i) +

(i),

(2.49)

YC(tl, i) =

∑

(v; tl, i) =

(tl; i) +

(i),

(2.50)

independently for i = 1, . . . ,k.
By the central limit theorem, the

(i) and the

distributed with means 0 and variance
The deviance

(i) are approximately normally

(tl; i) and

(tl; i), respectively.

(Y; i) of the density in (2.49) and the deviance

(Y; i) of

the density in (2.50) are given respectively by:
(Y; i) = log{ (tl; i)}− log ni(l) +
(Y; i) = log{ (tl; i)}− log ni(l) +
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;

;

× (YP (tl, i) −

(tl; i) .

(2.51)

× (YC(tl, i) −

(tl; i) .

(2.52)

Statistical Inference Procedures to Estimate Parameters
To estimate the unknown parameters in initiation-promotion experiments, the data
available are the number of animals with papillomas, the number of animals with
carcinomas, the average number of papillomas per mouse and the average number of
carcinomas per mouse. While the probability distribution of each of these variables is
readily available (see Section above), the joint probability distribution of these variables
are very complicated and remain to be derived. To make use of all data to estimate the
unknown parameters in the Bayesian approach, in this chapter we will employ two
different approaches: One approach is through the weighted average of the log of the
posterior distribution from different data sets, the other approach is sequential using
estimates from one data set as prior information for the posterior distribution using the
other data sets and vice versa; see Remark 2.2.
Remark 2.2. As shown in the next section, the fitting of some actual data from some
initiation-promotion experiments indicated that these two approaches yielded very similar
results.
The Bayesian Approach
In the Bayesian approach, because prior information about the genetic parameters
are vague and imprecise but previous biological information and studies provide some
lower bounds and upper bounds for the parameters, we will assume a partially noninformative prior for these parameters. That is, we assume the prior distribution as
proportional to positive constants within the bounded region but are zeros for otherwise.
We will derive the posterior modes as estimates. For easy of computation, we will use the
deviance of the posterior distribution which is the negative of the sum of the log of the
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prior and the log of the standardized likelihood function. Under non-informative prior or
partially non- informative prior (i.e., non-informative prior but with lower and upper
bounds for the parameters), the deviance of the posterior distribution is equivalent
numerically to the deviance function of the likelihood as defined in generalized linear
models (Nelder, 1989). It follows that deriving the posterior model is equivalent to
minimize the deviance function of the posterior distribution. Notice that under noninformative prior or partially non- informative prior, the estimates through deriving the
posterior mode are equivalent numerically to the maximum likelihood estimates under
constraints in the classical sampling theory approach.
Obviously, the traditional Newton-Raphson optimization would not work and is very
inefficient to minimize the deviance under constraints, because the deviances are
nonlinear and contain many unknown parameters. We would employ the genetic
algorithm (GA) to derive the optimal values of parameters simultaneously. The genetic
algorithm is an optimization process based on evolution principles involving gene
mutation or chromosomal aberrations, mating types (referred to as crossing over in GA),
as well as fitness-based selection.
In this thesis, we have used the genetic algorithm package “rgenoud” in “R”, which
was developed by Walter R. Mebane, Jr., and Jasjeet S. Sekhon. The advantages of using
“R” are:
(1) The control arguments are clearly defined and easy to implement.
(2) If the gradients of parameters in an objective function are easy to derive and
the estimating function is generally concave, the algorithm takes advantage of steepest
descent method to locate the neighborhood region of optima.
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(3) It takes advantage of pure genetic algorithm that global optima is searched
based on fitness of selection procedure; this procedure avoids being trapped in a local
optimum in the event that multiple local optima exist.
We will use this genetic algorithm in combination with the stochastic model of
carcinogenesis and the Bayesian procedures to derive estimates of the unknown
parameters (mutation rates, birth rates and death rates, etc.). In the Bayesian procedure,
we will use a partially non-informative prior as the parameters satisfy prior constraints
imposed by the cancer biological process.
Procedures to Estimate Parameters
We have used the above approach to estimate parameters in each experiment
described in Section 2.3. The procedures of estimating the parameters are given as
following:
(1) Data Augmentation:
Given parameter values, we use the stochastic equations shown in section 3 (for each
experiment) and the associated probability distributions to generate a large sample of Z(j)
= {X(j), U(j), j = 1, 2, …, TM}, where TM is the maximum time point under consideration,
and where X(j)’s are state variables and U(j)’s are augmented variables. Next we
combine these sample with the probably distribution of data given state variables and
parameters and use the weighted Bootstrap method due to Smith and Gelfant (1992) to
select a sample from this large sample, say Z j . This Z j is then a sample of size one
from the conditional probability distribution of Z(j) given data and given parameter
values. Numerically this is equivalent to the E-step of the E-M algorithm in the sampling
theory framework.
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(2) Estimation of parameters given Z j :
Taken Z j as mean values of the state variables and augmented variables from the
stochastic system model, we apply genetic algorithm (GA) to minimize the deviance
function given in section 2.4. These posterior modes are taken as estimates of the
parameters Θ.
(3) Back to step (1) with Θ . and continue until convergence.
Table 2
Data from Initiation Experiment

Agent

Dose
(µg/mouse)

No. Mice
Surviving

Mice with
Papillomasa

Papillomas
per mousea

(%)

B(a)P

Coke
Oven
Main

a

Mice
with
Carcinomasb

Carcino
mas per
mouseb

(%)

0

37

8

0.08

5

.05

2.52

40

45

0.5

5

0.07

12.6

40

73

1.8

20

0.2

50.5

39

100

5.8

25

0.25

101

38

95

10.2

30

0.33

100

38

50

0.63

10

0.1

500

39

90

3.7

54

0.59

1000

39

87

3.3

53

0.53

2000

40

78

3.1

48

0.48

Scored at 6 month; b Cumulative score at 12 month
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An Illustrative Example
In this section we use the actually data from Nesnow et al. (1982) to illustrate how to
estimate parameters in initiation-promotion experiments. Before stepping into parameter
estimation, we describe the experiments from which the data were generated.
Observations from Initiation-Promotion Experiments
Initiation Experiment. In this experiment, B(a)P and coke oven main are taken
as initiator. For each agent, 200 similar sencar mice were randomly assigned to 5 dose
groups, 40 mice of each group. A single application of B(a)P (or coke oven main) to each
mice is followed one week later by multiple application of the tumor promoter TPA. The
data is shown in Table 2.
In this experiments, clearly both the B(a)P and the coke over main are strong
carcinogens because both papillomas and carcinomas were observed. Thus these agents
can not only induce mutation of Ras gene to generate I1 cells but also generate
simultaneous mutation of both the Ras-gene and the p-53 gene to generate I2 cells. Notice
that both of these mutations are dose depend; however, because TPA has only one dose
level, the birth rates and death rates of the I1 and I2 cells are independent of dose levels.
Promotion Experiment. In this experiment, the Coke oven main was used as the
promoter and was applied weekly to sencar mice. The mice were initiated with a single
dose of 50.5 µg/mouse of B(a)P (benzo(a)pyrene) and are scored at 34 weeks. The
observed data are given in Table 3. Notice that in this experiment, data on carcinomas
were not recorded.
In this experiment, because the coke oven main is also a strong carcinogen, during
the promotion periods both the mutation rates from N to I1 and from N to I2 are dose
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Table 3
Data from Promotion Experiment
Mice with
Papillomasa

Dose
(µg/mouse)

(%)

Papillomas per
mousea

100

3

0.02

500

26

0.44

1000

53

1.2

2000

84

2.5

4000

100

8.2

a

Scored at 6 month; b Cumulative score at 12 month

dependent. Similarly, both the birth rates and the death rates of the I1 cells and the I2
cells are dose dependent.
Complete Experiment. In this experiment, the coke oven is used as both an
initiator and a promoter. After initiation by coke oven main in the first week, mice were
treated weekly with coke oven main at different dose levels; at the end of one year data
on carcinomas were measured and is summarized in Table 4.
In this experiment, both the mutation rates from N to I1 and from N to I2 are dose
dependent. Similarly, both the birth rates and the death rates of the I1 cells and the I2 cells
are dose dependent.
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Table 4
Data from Complete Carcinomas
Dose
(µg/mouse)

a

Mice with
Carcinomasa
(%)

Carcinomas per
mousea

100

5

0.05

500

36

0.36

1000

48

0.55

2000

82

1.0

4000

98

0.98

Scored at 6 month; b Cumulative score at 12 month

Estimation Scheme
Using data from the above three experiments, we will proceed to estimate genetic
parameters relevant to coke oven main, which include mutation rates, birth rates and
death rates. The basic reason we use all of the above experiments instead of just one
complete experiment is that none of a single experiment contain data on both papillomas
and carcinomas. We will proceed sequentially. That is, we use first experiment data to
estimate part of all parameters and then apply these estimated values to the next
experiment.
(a) Initiation Experiment. In above initiation experiment, the unknown parameters
are: mutation rate from normal cells to I1 cells (initiated by B(a)P or coke oven main),
mutation rate from normal cells to I2 cells for both agents, birth rate and death rate for I1
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and I2 cells (due to TPA). We will the estimated mutation rates of B(a)P in this
experiment as prior information in the promotion experiment and use the estimated
mutation rates of coke oven main as prior information in the promotion and complete
experiments. In this experiment, because the promoter is TPA, the birth rate and the
death rates of I1 and I2 cells are independent of dose levels and are not completely
independent of the birth rate and death rates of these cells in promotion and complete
experiments in which coke oven main is used as promoter. In this experiment, as in Tan
et al. (2001), the dose related mutation rate from the normal cell to I1 and from N to I2 are
represented respectively by:
log 1

(2.53)

log 1

(2.54)

and

and

From (2.53)-(2.54), obviously, it is only possible to estimate
from papillomas data and only

and

carcinomas data; from these it follows that only
information in the promotion experiment and only

from

can be used as prior
can be used as prior

information in the complete experiment.
From these we also have:
, ~

log 1

, ~

log 1
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(2.55)

(b) Promotion experiment. In promotion experiment, only papillomas response is
recorded (Table 3). Coke oven main is not only a promoter but also a carcinogen;
therefore papillomas are produced not only by initiator (B(a)P) at the initiation period,
but also by the coke oven main during the promotion periods. In this experiment, let ωr be
the mutation rates from theinitiator, and λr (ui) from the coke oven main. Notice that ωr is
dose independent and λr(ui) are dose level dependent. These rates are represented
respectively by:
log 1

50.5

50.5

(2.56)

log 1

(2.57)

where ur is the dose level of coke oven main, and where

and

have been

estimated from the initiator experiment.
Equation (2.18) shows that the probability to develop detectable papillomas depends
on dose level through γ1 and θI. The birth rate and death rate are represented as follow:
log 1
log 1
It follows that

, that is,
log 1

and

Five parameters, ω10,

log 1
, which is not a function of dose level.

, γ10, δ1 and θ1 can be estimated from the promotion

experiment.
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(2.58)

(c) Complete Experiment. In the complete carcinomas experiment, carcinomas are
produced from two pathways: One is from normal cells directly, where

has been

estimated from initiation experiment; the other one is produced through I1 cells, where all
parameters related to I1 cells are estimated from above two experiments. The rest of the
parameters will be estimated from the complete carcinomas experiment; here

in

(2.52) is a parameter related to mutation rate from normal cells to I2 cells, β10 and β11 the
mutation rates from I1 cells to I2 cells, γ20,and δ2 the parameters which are related to
proliferation rate, and θ2.
Parameters Estimation
All of the above parameters are estimated by using procedures described in section
2.5. Prior information is collected to provide the lower bound and upper bound for each
parameter. Table 5 gives the lower and upper bounds of parameters (prior information).
Two deviance functions will be used: One is for the number of mice with papillomas or
carcinomas, and the other is for the average number of papillomas or carcinomas per
mouse. These deviances are minimized iteratively as described in the estimate procedure.
Two approaches will be employed: One is the weighted deviance from different data
using equal weight. The other is sequential starting with one type of data by assuming
given initial values of the unknown parameters; the estimated parameters which minimize
one deviance are taken as initial value to minimize the second deviance and repeat and
continue until convergence. The estimated parameters and standard errors are also shown
in table 5. We used bootstrap method proposed by Efron (1982) to obtain standard error
for each parameter.
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Table 5
Lower Bound, Upper Bound and Estimates of Parameters
Parameters

Estimate

Standard
Error

Lower Bound

Upper Bound

201.83229819

26.42

100

1000

0.3374434

0.12

0.1

0.5

0.06664222

0.0083

0.01

0.5

3.38206134

0.22

1

10

0.05147995

0.01

0.01

0.2

8.222657628

0.348

1

100

0.25125966

0.095

0.1

0.5

0.001593745

0.00034

1.0E-05

0.01

0.523923978

0.019

0.1

1

0.059995162

0.0027

0.01

0.5

4.937317031

0.894

1

10

0.004955142

0.000397

0.001

0.1
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Table 6
Generated Number of Mice with Papillomas
Mice with
Papillomasa

Data

(%)

Dose level

a

Mice with
Papillomas Cacinomasa
per mousea
(%)

Cacinomas
per mousea

100

6

0.02

8

0.08

500

16

0.44

20

0.22

1000

58

1.09

43

0.45

2000

80

2.74

87

0.88

4000

100

3.07

92

1.02

Data is collected at 34th week; b Data is collected at 52th week

Simulation Study
To assess the usefulness of our models and methods, in this section we generate
some Monte Carlo data by assuming some parameters values. Then we use these
generated data as the observations to estimate parameters. Complete carcinomas
experiment contains both initiation and promotion procedures. The data we generated are
the number of mice with papillomas and the average number of papillomas per mouse at
t1, the number of mice with carcinomas and the average number of carcinomas per mouse
at t2 (t2 > t1).
Generating Simulated Data
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Table 7
Estimates of Parameters and Standard Error
Parameters

Original Parameters

Estimate

Standard Error

201

234.3

63.26

0.34

0.37

0.1

0.07

0.062

0.0059

3.38

3.88

0.199

0.05

0.057

0.014

8.2

8.39

0.73

0.25

0.2

0.08

0.0002

0.00017

0.000056

0.227

0.336

0.018

0.06

0.059

0.0036

4.94

4.89

0.95

0.005

0.0035

0.0005

Papillomas are developed as a result of single mutation, and the mutated cells are
proliferated to a detectable size. Therefore, papillomas are generated only from single
step of a single pathway.
The parameter values are given as following:
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201,

0.34,

0.07,

3.38,

number of cells in a detectable papillomas), and
0.0002 ,

0.227 ,

0.06 ,

4.94,

0.05,
8.2 ,

698 (the

0.25 ,

0.005 ,

698. The dose

levels are 100, 500, 1000, 2000, and 4000. We collected papillomas data at the 34th week
and collect carcinomas data at the 52th week for each dose level. The number of mice
with papillomas is generated from a binomial distribution and is given in Table 6. The
average number of papillomas per mouse is generated from a normal distribution with
Poisson means and Poisson varainces. Similarly, the carcinomas data are generated.
Table 8
Sensitivity Test
Parameters

Original Parameters

Average Change of
Responses (%)*

201

5.005

0.34

12.6

0.07

2.02

3.38

4.19E-07

0.05

0.61

8.2

2.0

0.25

4.85

0.0002

5.0

0.227

8.2

0.06

269.6

4.94

78.9

0.005

7.31
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Parameter Estimation
We use the same estimation procedures as above to estimate the unknown parameters.
The estimated values and standard errors are given in Table 7.
From results in Table 7, clearly, the estimates are very close to true values implying
that the models and methods we proposed are quite reliable.
Sensitivity Test
To test sensitivity of the model to a parameter, in the simulation we increase the value
of the parameter by 10% at a time and simulate responses (the number of mice with
carcinomas) of the experiment. By comparing the responses with those from the original
settings, we can assess the model’s sensitivity to each parameter; in this way we can
assess the reliability of the estimates. The result is given in Table 8.
Table 8 shows that the model is very sensitive to γ20 (the difference between birth
rate and death rate) and θ2. This implies the estimates of γ20 and θ2 from the model are
very reliable. On the other hand, it appears that the model is quite insensitive to θ1;
therefore, the response would not change significantly even if the value of θ1 assumes any
value in a relatively wide range. Thus it is practically impossible to estimate θ1 accurately
by using the model.
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3. A NEW STOCHASTIC AND STATE SPACE MODEL OF HUMAN COLON
CANCER: INCORPORATING MULTIPLE PATHWAYS

Introduction
In the past 15 years, molecular biologists and geneticists have revealed the basic
molecular and genetic mechanisms for human colon cancer. These mechanisms have
been linked to two avenues: The chromosomal instability (CIN) involving chromosomal
aberrations and loss of heterozygosity (LOH), and the micro-satellite instability (MSI)
involving mis-match repair genes and the creation of mutator phenotype (Chapelle, 2004;
Fodde et al., 2001; Fodde et al., 2001; Green & Kaplan, 2003; Hawkins & Ward, 2001;
Hisamuddin & Yang, 2004; Sparks, Morin, Vogelstein, & Kinzler, 1998; Peltonmaki,
2001). The pathway of the CIN avenue (also referred to as LOH pathway) involves
inactivation through genetic and/or epigenetic mechanisms, or loss, or mutation of the
suppressor APC gene in chromosome 5q (about 85% of all human colon cancers)
whereas the pathway of the MSI avenue involves mutation or epigenetic inactivation of
the mis-match repair suppressor genes (about 15% of all colon cancers). This leads to
multiple pathways for the generation of human colon cancer tumors with each pathway
following a stochastic multi-stage model and with intermediate transformed cells
subjecting to stochastic proliferation (birth) and differentiation (death). The goal of this
paper is to develop a stochastic model for human colon cancer to incorporate these
biological information and pathways. This paper is an extension of Tan and Zhang
(2008), Little and Wright (2003), and Little, Vineis and Li (2008). We note that besides
the multiple pathways considered above, Little and Wright (2003), Little (2008) and
Little et al. (2008) have also included mixture type of multiple pathways; however,
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because the mutation rates are very small, the chance of mixture type of pathways will be
extremely small in which case the Little model is equivalent to the model in Section 3.3.
For developing biologically supported stochastic model of carcinogenesis, in Section
3.2 we present the most recent cancer biology of human colon cancer. Using results from
Section 3.2, we develop in Section 3.3 a stochastic model for carcinogenesis of human
colon cancer involving multiple pathways. In Section 3.4 we derive a statistical model for
cancer incidence data of human colon cancer. By combining models from Sections 3.3
and 3.4, in Section 3.5 we develop a state space model for human colon cancer. In
Section 3.6, by using the state space model in Section 3.5, we develop a generalized
Bayesian inference procedure to estimate unknown parameters and to predict state
variables. To illustrate the applications of the model and methods, in Section 3.7 we
apply the model and methods to the colon cancer incidence data from SEER. Finally in
Section 3.8, we discuss the usefulness of the model and methods and provide some
conclusions from model and results.
A Brief Summary of Colon Cancer Biology
As discussed in the introduction, genetic studies have indicated that there are two
major avenues by means of which human colon cancer is derived: The Chromosomal
Instability (CIN) and the Micro-Satellite Instability (MSI). The first avenue is associated
with the LOH pathway involving the APC gene in chromosome 5q and the latter
associated with the micro-satellite pathway involving mis-match repair genes. The most
important oncogene is the β-Catenin gene in chromosome 3p22.
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The CIN (LOH) Pathway of Human Colon Cancer (The APC- β– catenin −Tcf −
myc pathway)
The CIN pathway involves loss or inactivation of the tumor suppressor genes - the
APC gene in chromosome 5q, the Smad-4 gene in chromosome 18q and the p53 gene in
chromosome 17p; see Remark 3.1. This pathway accounts for about 85% of all colon
cancers. It has been referred to as the LOH pathway because it is characterized by
aneuploidy /or loss of chromosome segments (chromosomal instability); see Remark 3.2.
This pathway has also been referred to as APC− β -catenin − Tcf − myc pathway because
it involves the destruction complex GSK-3β − Axin− APC which phosphorylates the βCatenin protein leading to its degradation; when both copies of the APC gene are
inactivated or mutated, the destruction complex is then inactive leading to accumulation
of free β-Catenin proteins in the cytoplasm which move to the nucleus to complex with
Tcf/Lef transcription factor to activate and transcript oncogenes myc, cyclin D and CD44.
(Free β -Catenin protein in the cytoplasm also binds with E-cadherin and β -Catenin to
disrupt the gap junction between cells, leading to migration and metastasis of cancer
tumors.)
Morphological studies have indicated that inactivation, or loss or mutation of APC
creates dysplastic aberrant crypt foci (ACF) which grow into dysplastic adenomas. These
adenomas grow to a maximum size of about 10 mm3; further growth and malignancy
require the abrogation of differentiation, cell cycle inhibition and apoptosis which are
facilitated by the inactivation, or mutation or loss of Smad-4 gene in 18q and the p53
gene in 17p. The mutation or activation of the oncogene H-ras in chromosome 11p and
/or mutation and/or activation of the oncogene src in chromosome 20q would speed up
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these transitions by promoting the proliferation rates of the respective intermediate
initiated cells (Jessup, Garllic, & Liu, 2002). This pathway is represented schematically
by Figure 8. The model in Figure 8 is a 6-stage model. However, because of the haploinsufficiency of the Smad4 gene (see Alberici, Jagmohan-Changur, & De Pater, 2006)
and the haplo-insufficiency of the p53 gene (Lynch & Milner, 2006), one may reduce this
6-stage model into a 4-stage model by combining the third stage and the fourth stage into
one stage and by combining the fifth stage and the sixth stage into one stage. This may
help explain why for single pathway models, the 4-stage model fits the human colon
cancer better than other single pathway multi-stage models (Leubeck & Moolgaokar,
2002). Recent biological studies by Green and Kaplan (2003) and others have also shown
that the inactivation or deletion or mutation of one copy of the APC gene in chromosome
5 can cause defects in microtubule plus-end attachment during mitosis dominantly,
leading to aneuploidy and chromosome instability. This would speed up the mutation or
inactivation of the second copy of the APC gene and increase fitness of the APC-carrying
cells in the micro-evolution process of cancer progression. This could also help explain
why the APC LOH pathway is more frequent than other pathways.
Remark 3.1. As observed by Sparks et al. (1998), instead of the APC gene, this
pathway can also be initiated mutation of the oncogene β -catenin gene; however, the
proportion of human colon cancer due to mutation of β -catenin is very small (less than
1%) as compared to the APC gene, due presumably to the contribution of the APC on
chromosome instability (Green & Kaplan, 2003). Similarly, the destruction complex can
become inactive either by the inhibition of GSK-3 β through the Wnt signaling pathway
(see Sparks et al. 1998) or the inactivation or mutation of the Axin protein, leading to
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accumulation of the β - Catenin proteins in the cytoplasm; but the proportion of colon
cancer caused by inhibition of GSK-3 β is also very small as compared to the colon
cancer cases caused by the CIN and the MSI pathways.
Remark 3.2. The APC gene in chromosome 5q acts both as a tumor suppressor gene
and an oncogene in initiating and promoting colon carcinogenesis. As an oncogene, the
APC gene acts dominantly in regulating microtubule plus-end attachment during mitosis
(Green & Kaplan, 2003). Thus, the inactivation or deletion or mutation of one copy of the
APC gene in chromosome 5 can cause defects in microtubule plus-end attachment during

Figure 8. The CIN Pathway of Human Colon Cancer
mitosis, leading to aneuploidy and chromosome instability. This would speed up the
mutation or inactivation of the second copy of the APC gene and increase fitness of the
APC-carrying cells in the micro-evolution process of cancer progression. This could also
help explain why the APC LOH pathway is more frequent than other pathways.
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The MSI (Micro-Satellite Instability) Pathway of Human Colon Cancer
This pathway accounts for about 15% of all colon cancers and appears mostly in the
right colon. It has been referred to as the MSI pathway or the mutator phenotype pathway
because it is initiated by the mutations or epigenetic methylation of the mis-match repair
genes (mostly hMLH1 in chromosome 3p21 and hMSH2 in chromosome 2p16) creating
a mutator phenotype to significantly increase the mutation rate of many critical genes 10
to 1000 times. Normally these critical genes are TGF-β RII, Bax (The X protein of bcl-2
gene), IGF2R, or CDX-2. The mis-match repair genes are hMLH1, hMSH2, hPMS1,
hPMS2, hMSH6 and hMSH3; mostly hMLH1 (50%) and hMSH2 (40%). This pathway is
represented schematically by Figure 9. As in the LOH pathway, assuming haploinsufficiency of tumor suppressor genes, one may approximate this pathway by a 5-stage
model.

Figure 9. The MSI Pathway of Human Colon Cancer
Morphologically, mutation or methylation silencing of the MMR gene hMLH1 or
hMSH2 generates hyperplastic polyps which lead to the generation of serrated adenomas.
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These adenomas develop into carcinomas after the inactivation, or loss or mutations of
the TGF-β RII gene and the Bax gene, thus abrogating differentiation and apoptosis. (Bax
is an anti-apoptosis gene.) In what follows, we let N denote the normal stem cells, Ji the
i−th stage cells in the MSI pathways. Then for sporadic MSI, the model is N →J1 → J2
→ J3 → J4 → J5 → cancer tumor.
The Major Signaling Pathways for Human Colon Cancer
Recent biological studies (Baylin & Ohm, 2006; Koinuma et al., 2006) have shown
that both the CIN and the MSI pathways involve the Wnt signaling pathway and the
destruction complex (this complex is a downstream of the Wnt signaling pathway), the
TGF-β inhibiting signaling pathway and the p53-Bax apoptosis signaling pathway, but
different genes in the CIN and MSI pathways are affected in these signaling processes. In
the CIN pathway, the affected gene is the APC gene in the Wnt signaling, the Smad4 in
the TGF- β signaling and the p53 gene in the p53-Bax signaling; on the other hand, in the
MSI pathway, the affected gene is the Axin 2 gene in the Wnt signaling, the TGF- β Receptor II in the TGF- β signaling and the Bax gene in the p53-Bax signaling. Because
the probability of point mutation or genetic changes of genes are in general very small
compared to epigenetic changes, one may speculate that colon cancer may actually be
initiated by some epigenetic mechanisms (Baylin & Ohm, 2006; Breivik & Gaudernack,
1999; Jones & Baylin, 2002). In fact, Breivik and Gaudernack (1999) showed that in
human colon cancer, either methylating carcinogens or hyper-methylation at CpG islands
would lead to G/T mismatch which in turn leads to Mis-match Repair (MMR) gene
deficiency or epigenetic silencing of the MMR genes and hence MSI (Micro-satellite
Instability); alternatively, either hypo-methylation, or bulky-adduct forming (BAF)
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carcinogens such as alkylating agents, UV radiation and oxygen species promote
chromosomal rearrangement via activation of mitotic check points (MCP), thus
promoting CIN (Chromosomal Instability). A recent review by Baylin & Ohm (2006)
have demonstrated that epigenetic events may lead to LOH and mutations of many genes
which may further underline the importance of epigenetic mechanisms in cancer
initiation and progression.

Figure 10. The Multiple Pathways of Human Colon Cancer
Based on the above biological studies, in this chapter we thus postulate that the
incidence data of human colon cancer are described and generated by a multi-stage model
involving 2 pathways as defined above. In this chapter, because of haploid-insufficiency
of the tumor suppressor genes {Smad4, p53, Axin, Bax, TGF − β – Receptor II}, the
number of stages for the CIN pathway and MSI are assumed as 4 and 5 respectively.
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Methods
Stochastic Multi-Stage Model of Carcinogenesis for Human Colon Cancer Involving
Multiple Pathways
From results of Section 3.2, it follows that the stochastic multi-stage model for
human colon cancer can be represented schematically by Figure 10.
In Figure 10, the model assumes that cancer tumors are generated by two pathways
with pathway 1 as a k1-stage multi-stage model involving Il (l = 1, . . . ,k1) cells and with
pathway 2 as a k2-stage multi-stage model involving Jr (r = 1, . . . ,k2) cells. (For human
Table 9
Transition Rates and Transition Probabilities for Human Colon Carcinogenesis
Transition

Transition Probability

1N → 1N, 1I1

α0(t)Δt

1N → 1N, 1J1

β0(t)Δt

1 Il → 2Il
1 Il → Death
1 Il → 1 Il, 1 Il+1

αl(t)Δt
l = 1,2…, k1-1

1 Jr → 2Jr
1 Jr → Death
1 Jr → 1 Jr, 1 Jr+1

Βr(t)Δt
r = 1,2…, k2-1
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colon cancer, k1 = 4, k2 = 5.) The state variables are then X t = {Il(t), l = 1, . . .,k1 − 1,
Jr(t), r = 1, . . . ,k2 − 1} and T (t), where T (t) denotes the number of cancer tumors at time
t and where Il(t) (Jr(t)) denote the number of the Il (Jr ) initiated cells for {l = 1, . . . ,k1 − 1
(r = 1, . . . ,k2 − 1)} respectively. Notice that because cell proliferation, cell differentiation
and apoptosis, mutation or genetic changes all occur during cell division and cell division
cycle, and because X t (t + Δt) develop from X t through cell divisions during (t, t +
Δt], one may practically assume that (X(t), t ≥ t0) is a Markov process with continuous
time, where t0 represents time at birth; one the other hand, T (t + Δt) may derive from Ik1
(Jk2) cells before time t, T(t) is in general not Markov (Fakir & Tan, 2009; Yakovlev &
Tsodikov, 1996). If one assumes that the Ik1 and Jk2 cells grow instantaneously into
cancer tumors as soon as they are generated, then one may also assume the T (t) as
Markov. In this case, as illustrated in Tan (1991), one may use standard Markov theory to
derive the probability generating function (pgf) of the probabilities of these variables and
hence the probability distribution of these variables. Let ψ x , l
1, … , k

1, z; t , t
I

1, … , k

1, y , r

ψ x, y, z; t , t denote the pgf of { X t , T(t)}. Let
I

J

α t , βr t , b , d , b , d

J

denote the mutation rates, the birth rates and the death

rates of {Il, Jr} cells as given in Table 9 respectively. If T(t) is Markov, then by using the
method of Kolmogorov forward equation of these variables (Tan, 1991), it can readily be
shown that ψ x, y, z; t , t satisfies the following partial differential equation (pde):
ψ x, y, z; t , t
λI t x
∑

1

g x ,x

λJ t y
;t

1 ψ x, y, z; t , t

ψ x, y, z; t , t

∑

g y ,y
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;t

ψ x, y, z; t , t

(3.1)
where λI (t) = N(t)α0(t), λJ (t) = N(t)β0(t),
g x ,x

;t

x x

g y ,y

;t

y y

1 bI t
1 b

J

x
t

and the initial condition is ψ x, y, z; t , t

1 dI t
1 d

y

J

x x
t

1 α t ,
1 β t

y y

(3.2)

1 given normal individuals at risk at time t0.

The above pde is in general very difficult to solve; further, even if the solution of this
equation can be derived, the results are very difficult to apply to estimate the unknown
parameters and to predict future cancer cases. Most importantly, T(t) may not be Markov
so that this theory is not applicable (Fakir, 2009; Yakovlev & Tsodikov, 1996). In this
chapter, we will thus propose an alternative approach through stochastic equations. It can
easily be shown through the method of pgf that if T(t) is Markov, then the stochastic
equation method is equivalent to the method of Markov theory; as we shall see, however,
the stochastic equation method is more powerful and does not need to assume Markov for
T(t).
The Stochastic Equation for State Variables
To derive stochastic equations for the state variables, let B

I

t B

J

t

be the

number of births of the Il (Jr) initiated cells during (t, t + Δt] {l = 1, . . . ,k1 − 1 (r = 1, . . .
,k2 − 1)}, D I t D

J

t

the number of deaths of the Il (Jr ) initiated cells during (t, t +

Δt] {l = 1, . . . ,k1 − 1 (r = 1, . . .,k2 − 1)} and M

I

t M

J

t

the number of mutation (Il

→ Il+1) (Jr →Jr+1) of Il (Jr) cells during (t, t +Δt] {l = 1, . . . ,k1 − 1 (r = 1, . . .,k2 − 1)}.
Also let M

I

t M

J

t

be the number of mutation of N → I1 (N → J1) during (t, t + Δt].
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Taking into account of all possible input and output of relevant cells, we have the
following stochastic equations for the state variables:
I t

Δt

I t

M

I

J t

Δt

J t

M

J

t

B

t

B

I

J

Because the transition variables { M

t

D I t ,l

t

D

I

t , M

J

1, … , k

t ,r
J

t ,B

1, … , k
I

1

(3.3)

1

t ,D I t ,B

(3.4)
J

t ,D

J

t } are

random variables, the above equations are stochastic equations. With the transition rates
as given in Table 9, it can readily be shown that to the order of o(Δt), the conditional
probability distributions of M

I

t and M

J

t given N(t) are Poisson with means λI(t)Δt

and λJ(t)Δt respectively whereas the conditional probability distributions of the numbers
of births and deaths given the staging variables (i.e., the Il(t) and Jr(t)) follow multinomial
distributions independently. That is,
M

I

t | N t ~ Poisson λI t Δt , independent of M

J

t

(3.5)

M

J

t | N t ~ Poisson λJ t Δt , independent of M

I

t

(3.6)

for l = 1, 2, …, k1-1,
B

I

t , D I t | N t ~ Multinomial I t ; b I t Δt, d I t Δt

(3.7)

for r = 1, 2, …, k2-1,
B

J

t ,D

J

t | N t ~ Multinomial J t ; b

J

t Δt, d

J

t Δt

(3.8)

where λI(t) = N(t)α0(t), λJ(t) = N(t)β0(t).
Because the number of mutations of the Il cells would not affect the size of the Il
population but only increase the number of Il+1 cells and because the mutation rate of Il
cells is very small (10-8 ~10-5), it can readily be shown that to the order of o(Δt), the
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conditional probability distribution of M
mean Il(t)αl(t)Δt independently of {B
M

I

I

I

t given Il(t) Il cells at time t is Poisson with

t , D I t } and other transition variables. That is,

t | N t ~ Poisson I t αI t Δt , l

independently of {B

I

1

1, 2, … , k

(3.9)

t , D I t } and other transition variables.

Similarly, we have that to the order of o(Δt),
M

J

t | N t ~ Poisson J t β t Δt , r

independently of {B

J

t ,D

J

1, 2, … , k

1

(3.10)

t } and other transition variables.

Using the probability distributions given by equations (3.5)-(3.10) and by subtracting
from the transition variables the conditional expected values respectively, we have the
following stochastic differential equations for the staging state variables:
dI t

I t

I t

Δt
I

l

1, … , k

where γ I t

t

B

I

DI t

t

I t γ I t Δt

t

e I t Δt
(3.11)

J t

J t

Δt
J

1, … , k

t α

I

1

dJ t

r

M

M

t β

J

t

B

J

t

J t γ J t Δt

t

1
bI t

D

J

e

t
J

t Δt
(3.12)

dI t ,γJ t

b

J

t

d

J

t

In the above equations, the random noises {e I t Δt, e

J

t Δt} are derived by

subtracting the conditional expected numbers from the random transition variables
respectively. Obviously, these random noises are linear combinations of Poisson and
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multinomial random variables. These random noises have expected value zero and are
un-correlated with the state variables {Il(t), l = 1, . . .,k1 − 1, Jr(t), r = 1, . . . ,k2 −1}. It can
also be shown that to the order of o(Δt), these random noises are uncorrelated with one
another and have variances given by:
Var e I t Δt
for l

1, … , k

1,

J

t Δt

Var e
for r

1, … , k

EI

t α

t Δt

EI t b I t

d I t Δt

o Δt
(3.13)

EJ

t β

t Δt

EJ t b

J

t

d

1,

J

t Δt

o Δt
(3.14)

The Expected Numbers
Let uI (l, t) = E[Il(t)] and uJ (r, t) = E[Jr(t)] denote the expected numbers of Il(t) and
Jr(t) respectively and write uI(0,t) = uJ(0,t) = N(t). Using equations (3.11)-(3.12), we have
the following differential equations for these expected numbers:
duI l, t

uI l, t γ I t

uI l

1, t α

t

(3.15)

l = 1, . . . ,k1 − 1,
duJ r, t

uJ r, t γ J t

uJ r

1, t β

t

r = 1, . . . ,k2 − 1.
The solutions of the above equations are:
uI 1, t

λI x e

λ

uJ 1, t

λJ x e

λ

uI l, t

uI l

I

dx

J

1, x e

dx
λ

I

dx, for l = 2, . . .,k1 − 1,

83

(3.16)

uJ r, t

uJ r

J

λ

1, x e

dx, for r = 2, . . .,k2 − 1.

If the model is time homogeneous, then λI (t) = λI, λJ (t) = λJ, αl(t) = αl and γ I t
γ I for l = 1, . . .,k1 – 1 and βr(t) = βr and γ J t

γ J for r = 1, . . .,k2 − 1. If the

proliferation rates are not zero and if γ I

γJ

γI

γ J for all l ≠ u and r ≠ v, then

the above solutions reduce to:
λI

uI 1, t

I

γ

I

eγ

1,

uI l, t

∑

A u eγ

uJ r, t

∑

B u eγ

λI ∏

where A u

uJ 1, t

I

λJ
γ

J

eγ

J

1

for l = 1, . . . ,k1 − 1;

J

for r = 1, . . .,k2 − 1
γI

∏

γI

,B u

λJ ∏

∏

γJ

γJ

The Probability Distribution of State Variables and Transition Variables
Although T (t) is not Markov, the random vector {X t , t ≥ t0} is Markov with
continuous time. To derive the transition probability of this process, denote by f(x, y : N,
p1, p2) the density at (x, y) of the multinomial distribution ML(N; p1, p2) with parameters
(N; p1, p2) and h(x; λ) the density at x of the Poisson distribution with mean λ. Then, using
the probability distributions given by equations (3.5)-(3.10), the transition probability of
this Markov process is, to order of o(Δt):
PX t

Δt X t

∑I

∏

∑I

h a l ,i ;t ;I

f l , i ; I t , b I t Δt, d I t Δt
∏

∑J

∑J

f m ,j ;J t ,b

J

h b m ,J ;t ;J
t Δt, d

J

t Δt
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t β

t Δt

t α

t Δt

where I0(t) = J0(t) = N(t), a(lu, iu; t) = Iu(t + Δt) − Iu(t) − lu + iu, u = 1, . . .,k1 − 1 and b(mv,
jv; t) = Jv(t + Δt) − Jv(t) −mv + jv, v = 1, . . . ,k2 − 1.
The above transition probability and hence the probability distribution of X t is too
complicated to be f much use. For implementing the Gibbs sampling procedure to
estimate parameters and to predict state variables, we use data augmentation method to
expand the model. Thus, we define the augmented variables U t
1, . . . , k

1, B

J

J

t ,D

t ,r

1, . . . , k

B

I

1 . (In what follows we will refer these

variables as the transition variables, unless otherwise stated.) Put Z t
Δt ′ ′. Then {Z t , t

t ,D I t ,l

X t ′, U t

t } is Markov with continuous time. Using the probability

distributions of the transition random variables given by equations (3.5)-(3.10), the
transition probability is P{Z t
PZ t

∆t Z t

∆t |Z t } is:

PX t

∆t X t , U t

P U t |X t

(3.17)

where
PU t X t
∏

fB

I

t , D I t ; I t , b I t Δt, d I t Δt

∏

fB

J

t ,D

J

t ;J t ,b

J

t Δt, d

J

t Δt

(3.18)

and
PX t
∏

∆t X t , U t
∏

h uI l, t ; I t α t Δt

where uI l, t
uJ r, t

I t
J t

Δt
Δt

h uJ r, t ; J t β t Δt

I t
J t

B

B

I

J

t

D I t for l = 1, . . .,k1 − 1 and

t
D

85

J

t for r = 1, . . . ,k2 − 1.

(3.19)

The probability distribution given by equation (3.17) will be used to derive estimates
and predicted numbers of state variables. This is discussed in Section 3.6.
A Statistical Model and the Probability Distribution of the Number of Detectable
Tumors
The data available for modeling carcinogenesis are usually cancer incidence over
different time periods. For example, the SEER data of NCI/NIH for human cancers are
given by {(yj, nj), j = 1, . . . ,n}, where yj is the observed number of cancer cases during
the j−th age group and nj is the number of normal people who are at risk for cancer and
from whom yj of them have developed cancer during the age group. Given in Table 10
are the SEER data for human colon cancer adjusted for genetic cancer cases.
The Probability Distribution of the Number of Detectable Tumors for Colon Cancer
To derive the probability distribution of time to tumors, one needs the probability
distribution of T(t). For deriving this probability distribution, we observe that malignant
cancer tumors arise by clonal expansion from primary Ik1 cells and primary Jk2 cells,
where primary Ik1 cells are Ik1 cells derived from Ik1−1 cells by mutation of Ik1−1 cells
and primary Jk2 cells are Jk2 cells derived from Jk2−1 cells by mutation of Jk2−1 cells.
I

Let PT

J

s, t (PT

s, t ) be the probability that a primary Ik1 (Jk2) cancer cell at time s

develops into a detectable cancer tumor at time t. Let Ti(t) be the number of cancer
tumors derived from the i−th pathway. Then, to order of o(Δt), the conditional probability
distribution of T1(t) given {Ik1−1(s), s ≤ t} is Poisson with mean ω1(t) independently of T2
(t), where
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,

. Similarly, to order of o(Δt), the

conditional probability distribution of T2(t) given {Jk2−1(s), s ≤ t} is Poisson with mean
ω2(t) independently of T1(t), where
,

.

Let Qi(j) (i = 1, 2) be defined by:
Q j

E e

ω

e

ω

E e

ω

1

eR

,

where Ri(tj-1,tj)=ωi(tj-1)-ωi(tj).
Then Qi (j) is the probability that cancer tumors would develop during the j−th age
group by the i−th pathway. Since cancer tumors develop if and only if at least one of the
two pathways yield cancer tumors, the probability that each normal person at time t0 will
develop cancer tumors during (tj−1, tj] is given by QT (j), where
QT (j) = 1−[1 – Q1 (j)][1 – Q2 (j)]= Q1 (j) + Q2 (j) – Q1 (j)Q2(j).
For practical applications, we observe that to order of o α

t

and o β

t

respectively, the ωi(t) in Qi(j) are approximated by
ω t ~

EI

s PTI s, t ds, ω t ~

s α

EJ

s β

J

s PT s, t ds.

Similarly, it can readily be shown that to the order of
Min o α

t

,o β

t

, QT(t) ~ Q1(t)+Q2(t). To further simplify the calculation

of QT(j), we observe that in studying human cancers, one time unit (i.e., Δt = 1) is usually
assumed to be 3 months or 6 months or longer. In these cases, one may practically
assume PTI s, t

J

1 and PT s, t

1 if t − s ≥ 1.
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A Statistical Model for Cancer Incidence Data
Let yj be the observed number of the number of cancer cases Yj developed during (tj−1,
tj] given nj people at risk for cancer, who are normal at birth (t0). We assume that each
individual develops colon cancer tumor by the same mechanism independently of one
another. Then for each person who is normal at birth (t0), the probability that this
individual would develop colon cancer tumor during the j-th age group (tj−1, tj] is given
by QT (j). It follows that the probability distribution of Yj given that nj is:
Yj ~ Binomial{nj,QT (j)}.

(3.20)

Because nj is very large and QT (j) is very small, approximately Yj is Possion with
mean τj = njQT (j). Notice that to the order of Max o α

t

,o β

t

, τj (and

hence the probability distribution of Yj) depends on the stochastic model of colon
carcinogenesis through the expected number {E[Ik1−1(t)], E[Jk2−1(t)]} of {Ik1−1(t), Jk2−1(t)}
and the parameters {α

t ,β

t } over the time period (tj-1, tj].

The State Space Model of Human Colon Cancer
State space model is a stochastic model which consists of two sub-models: The
stochastic system model which is the stochastic model of the system and the observation
model which is a statistical model based on available observed data from the system.
Thus, the state space model of a system takes into account the basic mechanisms of the
system and the random variation of the system through its stochastic system model and
incorporates all these into the observed data from the system; furthermore, it validates
and upgrades the stochastic model through its observation model and the observed data of
the system. As illustrated in Tan (2002), the state space model has many advantages over
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both the stochastic model and the statistical model when used alone since it combines
information and advantages from both of these models.
For human colon cancer, the stochastic system model of the state space model is the
stochastic model consisting of 2 pathways with each pathway following a multi-stage
model as described in Section 3.3; the observation model of this state space model is a
statistical model based on the observed number of colon cancer cases as described in
Section 3.4.
The Stochastic System Model and the State Variables
Putting Δt = 1 for some fixed small interval, then the staging variables are
X = {X t , t
t ,t

t ,t

1, … , t M

1, … , t M } and the transition variables are U = {U t , t

1}.

From results in Section 3.3, the joint probability distribution of {X, U} given the
parameters Θ is:
P X, U|Θ
where P U t

∏M
1 |X t

P X t |X t
1

1 ,U t

and P X t |X t

1

PU t

1 ,U t

1

1 |X t

1

(3.21)

are given by equations

(3.16) and (3.17) respectively and where
Θ={λI , λJ , α t , β t , b I t , d I t , b

J

t ,d

J

t , l = 1, . . .,k1 − 1, r = 1, . . . ,k2 −

1}.
Notice that this probability distribution is basically a product of Poisson distributions
and multinomial distributions.
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The Observation Model Using SEER Data
Put Y = (Yj, j = 1, . . . ,m) and y = (yj, j = 1, . . .,m). By the probability distribution
given by equation (3.18), the conditional probability density of Y given {X, U, Θ} is
approximately given by:
∏

P X, U|Θ

h Y;τ

(3.22)

where h(Yj ; τj) is the density at Yj of the Poisson distribution with mean τj. Then the
∏

likelihood function of Θ given (X,U) is L Θ|y, X, U

h Y ; τ . It follows that the

deviance from this density is:
Dev

2 logL Θ|y, X, U
τ̂ , j

where Θ

1, … , m and τ̂

∑

logL Θ y, X, U

y

τ

y log

τ

(3.23)

y is the maximum likelihood estimate of τj. From

equations (3.19)-(3.20), we have for the joint density of (X, U, Y) given Θ:
, ,

|

, |

| , ,

(3.24)

To apply the above distribution to estimate unknown parameters and to fit real data,
we also make the following assumptions: (a) From biological observations (Chapelle,
2004; Fodde et al., 2001; Fodde et al., 2001; Green & Kaplan, 2003, Hawkins & Ward,
2001, Hisamuddin & Yang, 2004; Peltonmaki, 2001; Sparks et al., 1998; Ward et al.
2001), one may practically assume that {α t
0, 1, 2, 3, 4; b

I

t

b I ,d I t

d I ,b

J

α ,l
t

b

J

0, 1, 2, 3; β t
,d

J

t

β, r

J

d }. (b) Because the

colon polyps are generated by proliferation of I2 cells and J3 cells and because the polyps
can only grow to a maximum size of about 10 mm3, we assume that {b I t
bIe

δ

,d I t

dIe

δ

} and {b

J

t

J

b e

δ

,d

J

t

J

d e

δ

} for some small

(δi> 0, i = 1, 2). (c) Because colon cell divisions are mainly due to action of the β90

Catenin gene, one may also assume {γ I t
approximately I t

Δt

I t

M

I

γJ t

0, j

t and J t

Δt

1, 2}. In this case, one has
J t

M

J

t ,r

1, 2.

Under these assumptions, the unknown parameters of interest are Θ = {Θ1, Θ2}, where
Θ

λI , λJ , α , β , β , b I , d I , b

J

,d

J

,i

1, 2, j

1, 2, δ , l

1, 2 and Θ2= (α3,

β4).
The Generalized Bayesian Method and the Gibbs Sampling Procedure
The generalized Bayesian inference is based on the posterior distribution
P

| , ,

of Θ given {X, U, Y = y}. This posterior distribution is derived by

combining the prior distribution P{Θ} of Θ with the probability distribution P{X,U,Y |Θ}
given by equation (3.20) with Y being replaced by y. It follows that this inference
procedure would combine information from three sources:
(1) Previous information and experiences about the parameters in terms of the prior
distribution P{Θ}; (2) Biological information represented by the stochastic system
equations of the stochastic system (P{X,U|Θ}); (3) Information from observed data,
represented by the statistical model through the conditional likelihood L(Θ| , X, U).
Because of additional information from the stochastic system model, this inference
procedure is advantageous over the standard Bayesian procedure in that it can avoid the
identifiability problems associated with standard Bayesian method. For example, we have
shown that to the order of Max o α t , o β t

the probability distribution of the

Yj’s depends on the stochastic model through the expected numbers of I3(t) and J4(t),
which depend on the birth rates and death rates only through the difference of these rates.
It follows that it is not possible to estimate the birth rates and death rates separately by
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the traditional Bayesian method. Most importantly, the number of parameters is very
large and the number of data points is limited. Thus, without information from the
stochastic system model, it is virtually impossible to estimate all unknown parameters;
for more examples, see Tan (2000, 2002).
The Prior Distribution of the Parameters
For the prior distributions of Θ, because biological information have suggested some
lower bounds and upper bounds for the mutation rates and for the proliferation rates, we
assume
P(Θ)

c (c > 0)

(3.25)

where c is a positive constant if these parameters satisfy some biologically specified
constraints; and equal to zero otherwise. These biological constraints are:
(i) For the mutation rates of the Ii cells in the LOH pathway, 1 < λI < 1000 (N → I1 ),
10-6 < αi< 10-4, i = 1, 2, 3. For the proliferation rates of Ii cells in the LOH pathway,
γ1(t) = 0, 0

b

I

0.5, i = 2, 3, γ I t

γIe

δ

, 10-2 < γ2 < 2 * 10-2, 10-5 < δ1 < 5

*10-3, 10−2 < γ2 < 0.5.
(ii) For the mutation rates in the MSI pathway, 1 < λJ < 1000 (N → J1), 10-8 < β1 <
10-5, 10-6 < βj < 10-2, j = 2, 3, 4. For the proliferation rates in the MSI pathway, γ
0, i

1, 2, γ J t

γJe

δ

J

t

J

, 10-3 < γ3J <0.5, j = 3, 4, 10-6 < δ2 < 5 *10-4, 0 < bj <0.5, j

= 3, 4.
We will refer the above prior as a partially informative prior which may be
considered as an extension of the traditional non-informative prior given in Box and Tiao
(1973).
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The Posterior Distribution of the Parameters Given {Y = , X, U}
Combining the prior distribution given in (3.6.1) with the density of P{X,U,Y |Θ}
given in equation (3.20), one can readily derive the conditional posterior distribution of Θ
given {X,U,Y =

∑ M I t ,B I

}. For (l = 2, 3), denote by: N I

∑M B

I

t ,D I

∑ M D I t ; similarly, for r = 3, 4, we define {BrJ , DrJ , NrJ} by replacing
(I t , B

I

t , D I t ) by (J t , B

J

t ,D

J

t ) respectively. Then, we have the

following results for the conditional posterior distributions:
(i) The conditional posterior distributions of Θ1(1) = {λI, λJ, αl, l = 1, 2, βr, r = 1, 2, 3}
given
{X,U,Y = y } is:
P Θ 1 |X, U, y
PΘ 1 e
λJ

λI λJ

∑M MJ

∑M MI

λI

M

N Iα

e

α

∑

e

,

2

(ii) The conditional posterior distributions of

N Jβ

β

,

∑

,

given

{X, U, Y = } is:
2 | , ,

2

,

,

,

,

,

,

,

(iii) The conditional posterior distribution of {α3, β4} given {X, U, Y =
,

| , ,

,
} is:

,
,

(vi) The conditional posterior distribution of {
,

and the conditional posterior distribution of {

, δ1} given {X, U, Y =

, δ2} given {X, U, Y =

} are

represented respectively by:
,

,

, ,

,

,

f(

,
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,

,

,

,

∏

1

}

,

,

, ,

,

,

f(

,

,

,

,

∏

1

The Multi-level Gibbs Sampling Procedure For Estimating Parameters
Given the above probability distributions, the multi-level Gibbs sampling procedure
for deriving estimates of the unknown parameters are given by:
(a) Step 1: Generating (X,U) Given (Y = y, Θ) (The Data-Augmentation Step):
Given Y = y and given Θ, use the stochastic equations (3.3)-(3.4) and the probability
distributions given by equations (3.5)-(3.10) in Section 3.3 to generate a large sample of
(X,U). Then, by combining this sample with P{Y = y | X,U,Θ} to select (X,U) through
the weighted bootstrap method due to Smith and Gelfant (1992). This selected (X,U) is
then a sample from P{X,U|Y = y, Θ} even though the latter is unknown.
(For proof, see Tan (2002), Chapter 3.) Call the generated sample X, U .
(b) Step 2: Estimation of Θ= {Θ1, Θ2} Given {Y = y, X, U}:

Figure 11. Estimated and Observed Colon Cancer Cases and Density of Time to Tumor
(2006 SEER data)
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Given Y = y and given (X, U) = ( X, U ) from Step 1, derive the posterior mode of
the parameters by maximizing the conditional posterior distribution P{Θ|X, U, y}. Denote
the generated mode as Θ.
(c) Step 3: Recycling Step.
With {(X,U) = (X, U , Θ
Θ } given above, go back to Step (a) and continue until
convergence.
The convergence of the above steps can be proved using procedure given in Tan
(2002, Chapter 3). At convergence, the Θ are the generated values from the posterior
distribution of Θ given Y = y independently of (X,U) (for proof, see Tan (2002), Chapter
3). Repeat the above procedures one then generates a random sample of Θ from the
posterior distribution of Θ given Y = y; then one uses the sample mean as the estimates of
Θ and use the sample variances and covariances as estimates of the variances and
covariances of these estimates.
Application to Fit the SEER Data
In this section, we will apply the above model to the NCI/NIH colon cancer 1996,

Figure 12. Estimated and Observed Colon Cancer Cases and Density of Time to Tumor
(2001 SEER data)
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2001, and 2006 data from the SEER project. Given in Table 10-12 are the numbers of
people at risk and colon cancer cases in the age groups together with the predicted cases
from the model for above three years, respectively. There are 18 age groups with each
I

group spanning over 5 years. To fit the data, we have assumed that γ1

J

γ1

0 for j =

1, 2 because of the observation that uncontrolled cell division of colon stem cells is
mainly initiated by the oncogene β-Catenin in 3p22. Given in Table 13-15 are the
estimates of the mutation rates, the birth rates and the death rates of the Ii cells and Jj
cells. Given in Figure 11-13 are plots of number of cancer cases probability density of
time to tumors.
From these results, we have made the following observations:
(a) As shown by results in Table 10-12 and Figure 11-13, the predicted number of
cancer cases is very close to the observed cases in all age groups for all three datasets.
This indicates that the model fits the data well and the mode is quite stable. Thus one can
safely assume that the human colon cancer can be described by a model of 2 pathways.
The AIC (Akaike Information Criterion) and the BIC (Bayesian Information Criterion)
from the model are 55.96 and 81.30 obtained from SEER 2006 data which are smaller
than the AIC of 816.0667 and the BIC value of 827.1513 from a single pathway 4-stage
model respectively (Luebeck & Moolgavkar, 2002). The AIC and BIC computed from
SEER 1996 and 2001 are also much smaller than those from single 4-stage pathway
model. This shows that the multiple pathway model fits better than the single pathway 4stage model as proposed by Luebeck and Moolgavkar (2002).
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Figure 13. Estimated and Observed Colon Cancer Cases and Density of Time to Tumor
(1996 SEER data)

Figure 14. Time to Tumor for Each Pathway (2006 SEER)
(b) From Table 10-12 and Figure 14-16, it is observed that the largest number of
cancer cases is in the age group between 70 and 75 years old. Comparing the values of
Qi(j) between the CIN pathway (i = 1) and the MSI pathway (i = 2), it appears that the
largest cancer cases is between the age group 80 and 85 years old for the CIN pathway
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Figure 16. Time to Tumor for Each Pathway (1996 SEER)

Figure 15. Time to Tumor for Each Pathway (2001 SEER)
and is greater than 85 years old for the MSI pathways. Presumably this might be due to
the fact that the MSI pathway has one more stage than the CIN pathway.
(c) Reflecting the contribution of the APC gene on chromosomal instability, results in
Table 13-15 showed that the mutation rates of the Ir cells from I1 → I2 and from I2 → I3
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had increased about 100 times and 1000 times respectively than the mutation rate from N
→ I1 cells. Similarly, due to the contribution to genomic instability by the mis-match
repair genes, the mutation rates from J1 → J2, from J2 → J3 and J3 → J4 had increased
about 5 102, 0.5 104 and 104 times respectively than the mutation rate from N → J1.
Notice also from Table 13-15 that the mutation rates from J1 → J2 → J3 → J4 are about 2
to 3 times of those from I1 → I2 → I3. As shown in probability plots (not shown here),
these increases have speeded up the time to cancer in the MSI pathway by about 5-10
years.
(d) Results in Table 13-15 showed that the mutation rates from I3 → I4 and from J4
→ J5 are of the order 10-6 which were about 102 → 103times smaller than the mutation
rates from I1 → I2 → I3 and from J1 → J2 → J3 → J4. These results might be the
consequence that we had ignored the stages of vascular carcinogenesis (i.e., angiogenesis
and metastasis; see Hanahan & Weinberg (2000) and Weinberg, 2007) by merging these
stages into the last stage. From Weinberg (2007, Chapters 13-14), notice that the
angiogenesis and metastasis are also multi-stage processes.
(e) Results in Table 13-15 showed that the proliferation rates (birth rate - death rate)
of the I3 cells and the J4 cells are of order 10-2which are much larger than the proliferation
rates of the I2 cells and the J3 cells, due presumably to the effects of the silencing or
inactivation of the cell cycle inhibition genes (Smad4 and TGF-β-RII) and the apoptosis
inhibition genes (p53 and Bax). Notice from Table 13-15 that the estimates of the
proliferation rates of the I2 and I3 cells are approximately equal to those of the J3 and J4
cells respectively. These results seemed to suggest that the genomic instabilities had little
effects on cell proliferations.
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Table 10
Colon Cancer Data from SEER 2006 (Overall Population)

*

Age Group

Number of
People at Risk

Observed
Colon Cancer
Cases

Predicted Colon
Cancer Cases*

0

9934747

1

0

0−4

38690768

2

0

5−9

48506058

2

6

10−14

49881935

35

44

15−19

50447512

104

164

20−24

51612785

337

370

25−29

54071811

847

965

30−34

54194486

1829

2080

35−39

50363957

3420

3534

40−44

46029771

6174

6698

45−49

40674188

10950

11072

50−54

36070434

18716

18256

55−59

31084543

27438

25875

60−64

26507762

37155

34867

65−69

22772688

47202

45156

70−74

18785224

53190

52810

75−79

14592602

52887

53479

80−84

9751212

42589

41517

The predicted numbers were generated by the model with unknown parameters
being substituted by the estimates respectively.

100

Table 11
Colon Cancer Data from SEER 2001 (Overall Population)

*

Age Group

Number of
People at Risk

Observed
Colon Cancer
Cases

Predicted Colon
Cancer Cases*

0

10133168

0

0

0−4

39407080

2

2

5−9

49548675

1

5

10−14

50738796

31

42

15−19

51758589

90

92

20−24

53154897

268

293

25−29

56279465

704

764

30−34

55641828

1532

1662

35−39

50895387

2859

3161

40−44

45268107

5065

5778

45−49

39358389

8954

9345

50−54

34911012

15309

15511

55−59

30414133

23349

22020

60−64

26715010

32760

31318

65−69

23364715

42119

41720

70−74

19125836

47209

46012

75−79

14548483

46122

45963

80−84

9492871

36432

35672

The predicted numbers were generated by the model with unknown parameters
being substituted by the estimates respectively.
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Table 12
Colon Cancer Data from SEER 1996 (Overall Population)

Age Group

Number of
People at Risk

Observed Colon
Cancer Cases

Predicted
Colon Cancer
Cases*

0−4

40207272

1

0

5−9

39633757

1

3

10−14

41046534

24

25

15−19

42500387

71

94

20−24

44400349

211

262

25−29

46227557

562

701

30−34

44888803

1205

1311

35−39

39700589

2181

2239

40−44

34570896

3839

3981

45−49

29704698

6753

7193

50−54

26561424

11973

11443

55−59

24278604

19111

17366

60−64

22008619

27362

26103

65−69

19243853

35062

34461

70−74

15271418

38503

38322

75−79

11245708

36605

37660

80−84

7237028

28710

29170

*

The predicted numbers were generated by the model with unknown
parameters being substituted by the estimates respectively.
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Table 13
Estimates of Parameters for Each Pathway (SEER 2006)
LOH Pathway

Mutation
Rate

I0

I1

I2

I3

1.4E-06

2.2E-04

3.2E-03

1.2E-06

±1.69E-08

±1.32E-05

±3.33E-04

±2.06E-07

0

0

3.6E-03

1.6E-02

N/A

N/A

±1.12E-03

±4.78E-04

0

0

7.4E-03

1.9E-02

N/A

N/A

±1.03E-03

±4.08E-04

N/A

N/A

Proliferation
Rate
Birth Rate
Para.
Growth
Limiting
Para.

8.3E-05
±1.4E-05

N/A

MSI Pathway

Mutation
Rate
Proliferation
Rate
Birth Rate
Growth
Limiting
Para.

J0

J1

J2

J3

J4

8.3E-07

3.5E-04

1.4E-03

9.3E-03

7.7E-06

±1.38E-08

±1.89E-05

±8.57E-05

±1.22E-03

±1.79E-06

0

0

0

2.8E-03

2.0E-02

N/A

N/A

N/A

±7.01E-04

±3.31E-04

0

0

0

9.6E-03

2.6E-02

N/A

N/A

N/A

±6.08E-04

±2.88E-04

N/A

N/A

N/A
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1.6E-03
±3.7E-04

N/A

Table 14
Estimates of Parameters for Each Pathway (SEER 2001)
LOH Pathway

Mutation Rate

I0

I1

I2

I3

1.38E-06

1.6E-04

1.6E-03

1.4E-06

±6.53E-09

±3.59E-06

±2.6E-05

±1.39E-07

0

0

4.6E-03

1.9E-02

N/A

N/A

±3.2E-04

±9.83E-05

0

0

6.2E-03

2.2E-02

N/A

N/A

±3.2E-04

±9.49E-05

N/A

N/A

Proliferation Rate

Birth Rate Para.
Growth Limiting
Para.

8.31E-05
±5.0E-05

N/A

MSI Pathway

Mutation
Rate
Proliferation
Rate
Birth Rate
Growth
Limiting
Para.

J0

J1

J2

J3

J4

8.42E-07

2.8E-04

1.1E-03

5.4E-03

9.67E-06

±5.48E-09

±6.01E-06

±1.38E-05

±7.29E-05

±3.93E-06

0

0

0

1.3E-02

1.8E-02

N/A

N/A

N/A

±1.95E-03

±6.33E-05

0

0

0

2.4E-02

1.9E-02

N/A

N/A

N/A

±1.77E-03

±5.64E-04

N/A

N/A

N/A
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6.5E-05
±1.5E-04

N/A

Table 15
Estimates of Parameters for Each Pathway (SEER 1996)
LOH Pathway

Mutation Rate

I0

I1

I2

I3

1.4E-06

1.5E-04

8.0E-04

1.9E-06

±6.4E-09

±5.05E-06

±3.84E-05

±2.48E-07

0

0

4.9E-03

2.0E-02

N/A

N/A

±3.54E-04

±1.63E-04

0

0

5.7E-03

2.1E-02

N/A

N/A

±3.5E-04

±1.46E-04

N/A

N/A

Proliferation
Rate
Birth Rate Para.
Growth
Limiting Para.

8.3E-05
±1.4E-05

N/A

MSI Pathway

Mutation
Rate
Proliferation
Rate

Birth Rate
Growth
Limiting
Para.

J4

J0

J1

J2

J3

8.5E-07

2.6E-04

1.1E-03

5.2E-03

±4.97E-08

±5.72E-06

±2.52E-05

±1.34E-04

0

0

0

1.8E-02

N/A

N/A

N/A

±3.1E-03

0

0

0

1.9E-02

N/A

N/A

N/A

±2.9E-03

±2.6E-04

N/A

N/A

N/A

3.6E-04

N/A
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±2.7E-04

1.7E-05
±6.46E-06
1.9E-02
±3.1E-04
2.0E-02

Conclusions and Discussion
Recent studies of cancer molecular biology have indicated very clearly that human
colon cancer is developed through multiple pathways (Chapelle, 2004; Fodde et al, 2001;
Fodde et al., 2001; Green & Kaplan, 2003, Hawkins & Ward, 2001, Hisamuddin & Yang,
2004; Peltonmaki, 2001; Sparks et al., 1998; Ward et al., 2001). This indicates that single
pathway models are not realistic and hence may lead to incorrect prediction and
confusing results. For developing efficient prevention and controlling procedures for
human colon cancer and for prediction of future human colon cancer, in this chapter we
have developed a stochastic model and a state space model for carcinogenesis of human
colon cancer involving multiple pathways with each pathway being a multi-stage model.
Using this model, we have derived for the first time the probability distribution of the
numbers of initiated cells and the probability distribution of time to cancer tumors. Such
derivation by the traditional approach is extremely difficult and had not been attempted
previously for multiple pathway models. Based on the state space model of colon cancer,
we have developed a generalized Bayesian procedure to estimate the unknown
parameters and to predict future cancer cases. This approach combines information from
three sources: The stochastic system model via P{X, U | Θ}, the prior information via
P{Θ} and information from data via L{Θ|y, X, U}. Because of additional information
from the stochastic system model, our procedure is advantageous over the standard
Bayesian procedure and the sampling theory procedure. Notice that there are a large
number of unknown parameters in the model and only a limited amount of data are
available. Without this additional information, it is then not possible to estimate all
unknown parameters. Notice also that through the stochastic system model, one can
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incorporate biological mechanism into the model. Because the number of stages and the
mutation rates of intermediate cells in different pathways are different and different drugs
may affect different pathways, we believe that this is important and necessary.
We have applied these models and procedure to three different NCI SEER data (up to
November, 2007). Our results showed that the proposed multiple pathways model was
quite reliable and fitted better than the single pathway 4-stage model as proposed by
Luebeck and Moolgavkar (2002). (The respective AIC and BIC for the multiple pathways
model are 55.96 and 81.30 which are 10 times smaller than those of the AIC (816.0667)
and BIC (827.1513) respectively of the single pathway 4-stage model.)
In this preliminary study, we have not yet compared the multiple pathways model
with the single pathway model regarding prediction of future cancer cases and evaluation
of treatment protocols for human colon cancer. This will be our future research, and we
will not go any further here.
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4. A STOCHASTIC AND STATE SPACE MODEL OF HUMAN LIVER
CANCER-MULTIPLE-PATHWAY MODEL INVOLVING BOTH HEREDITARY
AND NON-HEREDITARY CANCER

Introduction
It is well documented that each cancer tumor is derived from a single stem cell which
has sustained a finite number of genetic and epigenetic changes and with intermediate
cells subjecting to stochastic cell proliferation and differentiation. That is, carcinogenesis
is a stochastic multi-stage process involving genetic and epigenetic changes and
stochastic cell proliferation and cell differentiation. Recent studies by molecular
biologists have also shown clearly that for many human cancers (colon cancer, liver
cancer, lung cancer and melanoma, etc.; see Little (2008), Tan (1991), Tan et al. 2008a,
2008b), the same cancer can be derived by multiple pathways with each pathway being a
multi-stage model. In Tan et al. (2008a) and Tan and Yan (2009), we have developed
multiple pathway models for human colon cancer. The major stages for human liver
cancer development, on the other hand, have been identified by histopathological
evidence though genetic signaling pathways have not been well established. In this
chapter we develop a multiple-pathway model for human liver cancer, including nonhereditary hepatocelluler carcinoma and hereditary hepatoblastoma.
For developing biologically supported stochastic model of carcinogenesis, in Section
4.2 we present the most recent cancer biology of human liver cancer. Using results from
Section 4.2, in section 4.3 we develop a multi-stage model for carcinogenesis of nonhereditary human liver cancer, involving multiple pathways. In Section 4.4 we derive a
statistical model for cancer incidence data of non-hereditary human liver cancer. And
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then we extend the multiple-pathway multiple-stage model to incorporate inherited liver
cancer, which is shown in Section 4.5. In Section 4.6 we derive a statistical model for
cancer incidence data of hereditary human liver cancer. By combining models from
Sections 4.3 - 4.6, in Section 4.7 we develop a state space model for human liver cancer.
In Section 4.8, by using the state space model in Section 4.7, we develop a generalized
Bayesian inference procedure to estimate unknown parameters and to predict state
variables. To illustrate the applications of the model and methods, in Section 4.9 we
apply the model and methods to the liver cancer incidence data from SEER. Finally in
Section 4.10, we discuss the usefulness of the model and methods and provide some
conclusions.
A Brief Summary of Liver Cancer Biology
Hereditary Liver Cancer
The molecular biologists and clinicians have shown that mechanisms of developing
embyronal liver cancer (hepatoblastoma, or HBL) are quite different from these for
sporadic liver cancer (Dufour & Clavien, 2010; Grisham, 2002; Hirschman & Tomlinson,
2005). HBL occurs almost exclusively in infants and children 4 years of age or younger,
especially in children with a family history of Familial adenomatous polyposis (FAP).
Clinical studies indicated no association between HBL and hepatitis infection, maternal
estrogen exposure and cigarette smoking (Grisham, 2002). The major genetic mutation in
FAP is mutation of adenomatous polyposis coli (APC) gene (Hirschman & Tomlinson,
2005). According to this mechanism for HBL, the individual is in the first stage (A1
stage) if one copy of the APC gene has been lost or mutated or inactivated, in the second
stage (A2 stage) if both copies have been lost or mutated or inactivated.
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Non-hereditary Liver Cancer
For sporadic liver cancer, the primary hepatocellular neoplasms, on the other hand,
occur at all ages and consist of hepatocellular adenoma (HCA), hepatocellular carcinoma
(HCC). HCA is benign but HCC is malignant. HCA is extremely rare occurring mainly in
hepatocyte which lack both chronic hepatitis and cirrhosis. From these observations, to
model sporadic human liver cancer (i.e., after age 15 years old), one may practically
ignore HCA but only concern HCC. We give a brief summary of the mechanisms of
HCC.
Risk Factors. HCC is a fatal malignant cancer with the majority of cases (90-95%)
occurring in hepatitis B virus (HBV, over 65%) and hepatitis C virus (HCV, over 20%)
carriers (Wands, 2004). Other important risk factors are food contamination with
aflatoxin (AFB1), alcohol consumption, smoking, exposure to arsenic or vinyl chloride,
high intake of iron and low intake of antioxidant vitamins and selenium. HCC is rare in
the United States and Western Europe because of the low infection rate of HBV in these
areas, but it is one of the most common malignancies in Taiwan, Southern China
(Qidong, China) and Africa, due presumably to the high incidence of HBV, HCV and
AFB1 contamination in these areas. HCC is rising in US due to rampant spread of HCV
among US population between 1970 and 1990 via contaminated blood product, needle
sharing, etc.; see DeFrances (2005).
The Multi-stage Model and Multiple Pathways for HCC. Non-diseased liver
hepatocyte (denoted by NL) are long-lived cells with little turnover. When infected by
HBV or HCV, the liver develops into a liver with chronic hepatitis hepatocyte (denoted
by CH), which can further develop into cirrhosis (denoted by CC), a diffuse form of

110

hepatic fibrosis. (Cirrhosis may also be induced by alcohol intake or other factors than
HBV and HCV, but the incidence of HCC in cirrhosis without hepatitis infection is low
(< 15%) when compared to the incidence of HCC in cirrhosis with HBV /or HCV, see
Craig (2003). HCC can either develop from cirrhosis (60-80%) by following the multistage model: NL → CH → CC →PAH (denoted by PAH1) → DH (denoted by DH1) →
HCC, or from chronic hepatitis hepatocyte (20-40%) by following the multistage model:
NL → CH → PAH (denoted by PAH2) → DH (denoted by DH2) → HCC; see Figure 17
as proposed by Thorgeirsson and Grisham (2002). In these multi-stage models, the
intermediate lesions of pre-neoplastic hepatocyte are PAH (Foci of Phenotypically
Altered Hepatocyte), and DH (Dysplastic Hepatocyte). Notice that the PAH and DH from
the first pathway are different from those of the second pathway because the former cells
carry more genetic and epigenetic changes than those from the latter pathway
respectively (Grisham, 2002; Thorgeirsson & Grisham, 2002, Yeh et al., 2001). Also,
because the first pathway accounts for about 60-80% of all HCC, the proliferation rates
and mutations rates of the PAH1 cells and DH1 cells are considerably greater than those
of the PAH2 cells and DH2 cells respectively.
Some Relevant Biological Information for Modeling HCC. To develop stochastic
models of HCC along the above pathways, the following observations are useful
information which needs to be taken into account. In this chapter, we will integrate this
information into the models through partial informative prior as proposed by Tan et al.
(2008a).
All lesions (CC, FAH, DH) and HCC are clonal deriving from a single hepatocyte
which has sustained irreversible genetic or epigenetic changes with the latter stage lesions
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accumulate more changes (Breuhahn, Longerich, & Schirmacher, 2006; Buendia, 2000;
Chen & Chen, 2002; Grisham, 2002; Moradpour & Wands, 2003; Pogribny, Rusyn, &
Beland, 2008; Shih et al., 2006; Thorgeirsson & Grisham, 2002; Villanueva, Newell,
Chiang, Scott, & Llovet, 2007; Yeh et al., 2001;). Genomic alterations appear to be
developed randomly beginning in pre-neoplastic stages CH and CC, and escalating in
PAH, DH, and HCC. Thus, all important genetic changes may appear in any of CH, CC,
PAH, DH, and HCC but the frequencies of different genetic changes may be very
different between these stages, due to different cell micro-environment in the liver at
different stages and interactions with hepatitis infection. For example, for the percentage
of hepatocyte with activated telomerase, there are 4% in CH, 8% in CC, 55% in DH and
84% in HCC respectively; for aberrant methylation, 10% in CH, 16% in CC, 15% in DH,
and 40% in HCC respectively.
In normal liver cells and normal hepatocyte (NL cells), both the proliferation rate and
the death rate are very small and the birth rate is equal to the death rate. On the other
hand, both of these rates are increased in CH, CC, the intermediate lesions and in HCC
and the birth rate in these cells is always greater than the death rate respectively. Further
these rates of cells in more advanced stages are always greater than those of cells in less
advanced stages. This is probably the consequence of biological results that advanced
stages have accumulated more genetic and epigenetic changes; see Grisham (2002)
Pogribny et al. (2008), and Villanueva et al. (2007).

A Multi-Stage Model of Carcinogenesis for HCC

112

From results of Section 4.2, it follows that the stochastic multi-stage model for HCC
can be represented schematically by Figure 17.
In Figure 17, the model assumes that cancer tumors are generated by two pathways
with pathway 1 as a k1-stage multi-stage model (N →
involving normal stem cell N and
1)-stage multi-stage model ( →
.,
...,

− 1) cells. (For HCC,
− 1, (t), j = 1, . . . ,

=

→...→

→ Tumor)

(i = 1, . . . , ) cells and with pathway 2 as a (
...→

→ Tumor) involving

= 3.) The state variables are then
− 1}, {

(t),

and

(j = 1, . .

= { (t), i = 1,

(t)} and T(t), where T(t) denote the

number of cancer tumors at time t and where (t) ( (t)) denote the number of the
initiated cells for {i = 1, . . . ,
{

,t≥

−1 (j = 1, . . . ,

+

( )

−1)} respectively. Notice that while the

} is a Markov process with continuous time, T(t) in general may not be

I1= Chronic Infected Hepatocyte Stage
J1= Cirrhosis Stage
I2(J2) = PAH (Phenotype of Adhered Hepatocyte)
I3(J3) = DH (Dysplastic Hepatocyte)

Figure 17. A Two-Pathway Model for HCC
Markov; see Remark 4.1. If one assumes that the

and

cells grow instantaneously

into cancer tumors as soon as they are generated, then one may also assume the T(t) as
Markov and identify {

(t),

(t) as T(t). In this case, as illustrated in Tan (1991), one

may use standard Markov theory to derive the probability generating function (pgf) of the
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probabilities of the these variables and hence the probability distribution of these
variables (i.e.,

, T(t)). Because T(t) may not be Markov (Yakovlev & Tsodikov,

1996) and because cancer progression from {

,

} cells to cancer tumors may have

some important impacts on tumor development (Fakir, Tan, Hlatky, Hahnfeldt, & Sachs,
2009), in this paper, we will thus propose an alternative approach through stochastic
equations. It can easily be shown through the method of pgf that if T(t) is Markov, then
the stochastic equation method is equivalent to the method of Markov theory; as we shall
see, however, the stochastic equation method is more powerful and does not need to
assume Markov for T(t).
Remark 4.1. Because cell proliferation, cell differentiation and apoptosis, mutation
orgenetic changes all occur during cell division and cell division cycle, and because
Δ

develop from

assume that (

,t≥

through cell divisions during (t, t + Δt], one may practically
) is a Markov process with continous time, where

time at birth; on the other hand, T(t + Δt) may derive from

(

represents

) cells before time t, T(t)

is in general not Markov (Fakir et al., 2009; Yakovlev & Tsodikov, 1996).
The Stochastic Equation for State Variables
To derive stochastic equations for the state variables, let
number of birth of the
,

− 1)},

(t) (

Δt] {i = 1, . . . ,
(

→

,

−1)}. Also let

(t) (

(t)) be the

( ) initiated cells during (t, t + Δt] {i = 1, . . . ,
(t)) the number of death of the

− 1 (j = 1, . . . ,

+1) ( → +1) of
(t) (

− 1)} and

(t) (

( ) initiated cells during (t, t +
(t)) the number of mutation

( ) cells during (t, t+Δt] {i = 1, . . . ,
(t)) be the number of mutation of N →
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− 1 (j =1, . . .

− 1 (j =1, . . .
(

→ ) during

(t, t+Δt]. By the conservation law, we have then the following stochastic equations for the
state variables:
(t+Δt) = (t) +

(t) +

(t+Δt) = (t) +

(t) +

(t) −

(t), i = 1, . . . ,

− 1,

(4.1)

(t) −

(t), j = 1, . . . ,

− 1,

(4.2)

(t),

Because the transition variables {

(t),

(t),

(t),

(t),

(t)} are

random variables, the above equations are stochastic equations. To derive the probability
distributions of these transition variables and hence the probability distribution of state
variables, let the transition rates (mutation rates, birth rates and death rates) of the state
variables as given in Table 16. Then, as shown in Tan et al. (Tan, Zhang, & Chen, 2004),
we have that to the order of o(Δt), the conditional probability distributions of
given N(t) and of
respectively, where

(t) given (t) are Poisson with means
(t) = N(t)

(t) and

(t) = (t)

(t)Δt and

(t)

(t)Δt

( (t).

Similarly, it is shown in Tan et al. (2004) that the conditional probability distributions
of the numbers of births and deaths given the staging variables (i.e., the (t) and (t))
follow multinomial distributions independently. That is,
(t)|N(t) ~ Poisson{ (t)Δt}, independently of
(t)|I1(t) ~ Poisson{
for i = 1, 2, . . . ,
{

(t),

(t);

Δ }, independently of

(4.3)
(t);

(4.4)

− 1,
(t)}| (t) ~ Multinomial{ (t);

for j = 1, . . . ,

− 1,
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(t)Δt,

(t)Δt};

(4.5)

{

(t),

(t)}| (t) ~ Multinomial{ (t);

(t)Δt,

(t)Δt}.

(4.6)

Table 16
Transition Rates and Transition Probabilities for Human Liver Carcinogenesis
1N

1 N, 1 I1

α0(t)Δt + o(Δt)

1 I1

1 I 1 , 1 J1

β0(t) Δt + o(Δt)

1 Ii

2 Ii

1 Ii

death

1 Ii

1 Ii, 1 Ii+1

αi(t)Δt + o(Δt)

i = 1, …, k1– 1
1 Jj

2 Jj

1 Jj

death

1 Jj

1 Jj, 1 Jj+1

βj(t)Δt + o(Δt)

j = 1, …, k2– 1

Because the number of mutations of the

cells would not affect the size of the

population but only increase the number of
cells is very small (10

~ 10 ), it can readily be shown that to the order of o(Δt), the

conditional probability distribution of
Δ independently of {
(t)| (t) ~ Poisson{
independently of {

cells and because the mutation rate of

(t),

(t),

(t) given

cells at time t is Poison with mean

(t)} and other transition variables. That is,

Δ }, i = 1, . . . ,

− 1,

(t)} and other transition variables.

Similarly, we have that to the order of o(Δt),
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(4.7)

(t)| (t) ~ Poisson{ (t)
Independently of {

(t),

(t)Δt}, j = 1, . . . ,

− 1,

(4.8)

(t)} and other transition variables.

Using the probability distributions given by equations (4.3)-(4.8) and by subtracting
from the transition variables the conditional expected values respectively, we have the
following stochastic differential equations for the staging state variables:
Δ
Δ ,

Δ

1, … ,

1

(4.9)

Δ
Δ

Δ

(4.10)

Δ
Δ ,

Δ
where

(t) =

(t) −

(t),

1, … ,

1

(t) =

(t) −

In the above equations, the random noises {

(4.11)
(t).
(t)Δt,

(t)Δt} are derived by

subtracting the conditional expected numbers from the random transition variables
respectively. Obviously, these random noises are linear combinations of Poisson and
multinomial random variables. These random noises have expected value zero and are
uncorrelated with the state variables { (t), i = 1, . . . ,

− 1, (t), j = 1, . . . ,

− 1}. It

can also be shown that to the order of o(Δt), these random noises are un-correlated with
one another and have variances given by:
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Δ

Δ

for i = 1, . . . ,

Δ

− 1,

Δ

Δ

Δ

Δ
for j = 2, . . . ,

Δ

Δ

Δ

Δ

Δ

− 1,

(t) = N(t).

where

The Expected Numbers
Let

(i, t) =

and

(t) respectively and write

(j, t) =
(0, t) =

denote the expected numbers of (t) and
(0, t) = N(t). Using equations (4.9)-(4.11), we

have the following differential equations for these expected numbers:
,

,

1,

1,

,

,

1,

,

1, … ,

1

1,

,

1, … ,

1

1,

The solutions of the above equations are:
1, t

,

1, t

(4.12)

i, t

1,

,

2, … ,

1

(4.13)

i, t

1,

,

2, … ,

1

(4.14)

The Probability Distribution of State Variables and Augmented State Variables
Although T(t) is not Markov, the random vector

{, t ≥ t0} is Markov with

continuous time. To derive the transition probability of this process, denote by f(x, y : N,
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p1, p2) is the density at (x, y) of the multinomial distribution ML(N; p1, p2) with
parameters (N; p1, p2) and h(x : λ) the density at x of the Poisson distribution with mean λ.
Then, using the probability distributions given by equations (4.3)-(4.8), to order of o(Δt)
the transition probability of this Markov process is:
∏

Δ
,

;

, ;
∏

Δ ,

,
∑

, ;

,

∑

Δ ,

, ;

∑

Δ

∑

;
, ;

Δ
;

Δ

Δ

∑

, ;

,

∑

Δ ,

;

Δ

Δ

(4.15)

where I0(t) = N(t), a(mu, iu; t) = Iu(t +Δt)−Iu(t)−mu+iu, u = 1, . . . ,k1−1 and where
b(rv, jv; t) = Jv(t +Δt) − Jv(t) − rv + jv, v = 1, . . . ,k2 − 1.
The above transition probability and hence the probability distribution of

is too

complicated to be of much use. For implementing the Gibbs sampling procedure to
estimate parameters and to predict state variables, we use data augmentation method to
expand the model. Thus, we define the augmented state variables
,

,

1, … ,

,

1;

,

1, … ,

1 (In what

follows we will refer these variables as the transition variables, unless otherwise stated.)
,

Put

, then

,

is Markov with continuous time.

Using the probability distributions of the transition random variables given by equations
(4.3)-(4.8), the transition probability
Δ

Δ

,

119

(4.16)

∏

where
∏

,

,

;

,

;

Δ ,

,

Δ ,

Δ

Δ

(4.17)

and
Δ

,

∏

,

;

Δ

∏

,

;

Δ

where uI i, t
J t

Δt

I t

J t

B

Δt
J

t

I t
D

J

1,

;

Δ
(4.18)

B

I

D I t for i = 1, . . . ,k1 − 1 and uJ i, t

t

t for j = 1, . . . ,k2 − 1.

The probability distribution given by equation (4.15) will be used to derive estimates
and predicted numbers of state variables. This is discussed in Section 4.6.
A Statistical Model and the Probability Distribution of the Number of Detectable
Tumors for HCC
The data available for modeling carcinogenesis are usually cancer incidence over
different time periods. In this section, we will derive the cancer incidence function for
two pathways discussed in Section 4.3.
The Probability Distribution of the Number of Detectable Tumors for HCC
To derive the probability distribution of time to tumors, one needs to find the
probability distribution of T(t). For deriving this probability distribution, we observe that
malignant cancer tumors arise by clonal expansion from primary
cells, where primary
cells and primary

cells are
cells are

cells derived from
cells derived from
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cells and primary

cells by mutation of
cells by mutation of

cells.

,

Let

,

(

) be the probability that a primary

(

) cancer cell at time

s develops into a detectable cancer tumor at time t. Let Ti(t) be the number of cancer
tumors derived from the i−th pathway. Then, to order of o(Δt), the conditional probability
distribution of T1(t) given

(s), {s ≤ t} is Poisson with mean

independently of

T2(t), where
,

(4.19)

Similarly, to order of o(Δt), the conditional probability distribution of T2(t) given
(s), {s ≤ t} is Poisson with mean

independently of T1(t), where
,

(4.20)

(i = 1, 2) be defined by:

Let

,

1
,

where
Then

(4.21)

.
is the probability that cancer tumors would develop during the j−th age

group by the i−th pathway. Since cancer tumors develop if and only if at least one of the
two pathways yield cancer tumors, the probability that a normal person at time t0 will
develop cancer tumors during (tj−1, tj] is given by
1

1

, where

1

(4.22)

For practical applications, we observe that to order of o(
respectively, the

in

) and o(

)

are approximated by

~

,

(4.23)

~

,

(4.24)
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Similarly, it can readily be shown that to the order of Min{o(

), o(

)},

.
To further simplify the calculation of

, we observe that in studying human

cancers, one time unit (i.e., Δt = 1) is usually assumed to be 3 months or 6 months or
longer. In these cases, one may practically assume

,

~ 1 and

,

~ 1 if t – s

≥ 1.
A Statistical Model for Cancer Incidence Data
Let yj be the observed number of cancer cases during (tj−1, tj] given nj normal people
at risk at t0 for cancer. We assume that each individual develops colon cancer tumor by
the same mechanism independently of one another. Then for each normal person at time
t0, the probability that this individual would develop liver cancer tumor during the j-th
age group (tj−1, tj ] is given by

. It follows that the probability distribution of yj

given that nj people are at risk for liver cancer at time t0 is:
~
where

(4.25)
.
), o(

Notice that to the order of Max{o(

)}, τj (and hence yj) depends

on the stochastic model of liver carcinogenesis through the expected number {
,

} of {

,

} and the parameters {

,

} over the time period (tj−1, tj].
A Stochastic Model for Hereditary Liver Cancer (HBL)
Hirschman, Pollock, and Tomlinson (2005) has discovered the mutated APC gene is a
HBL-associated germ line mutation, it follows that the germ line cells (eggs and sperms)
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may carry the mutant APC allele so that liver cancer may occur at birth or at a young age.
Table 17
Liver Cancer Data from SEER (2008)
Age Group

Number of
People at Risk

Observed Liver
Cancer Cases

Predicted Liver
Cancer Cases

0

12,069,564

126

126

0-4

46,971,230

182

169

5-9

58,891,282

49

58

10−14

60,616,195

54

48

15−19

61321678

62

52

20−24

62,699,020

98

91

25−29

65,530,352

148

151

30−34

65,677,509

220

238

35−39

61,351,859

406

440

40−44

56,337,973

814

871

45−49

50,065,865

1720

1688

50−54

44,430,452

2665

2601

55−59

38,337,957

3083

2894

60−64

32,444,455

3415

3383

65−69

27,712,647

3725

3762

70−74

22,840,369

3948

3770

75−79

17,813,869

3541

3397

80−84

11,981,840

2275

2256
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Table 17
Liver Cancer Data From SEER (2008) (continued)
aa

AA
Genotype

I

J

Genotype

Aa
Genotype

pathway

pathway

126

0

0

0

0

0

169

0

0

0

0

57

0

0

1

0

32

1

2

13

0

11

1

5

35

0

4

2

11

74

0

1

3

23
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0

0

4

39

195

0

0

5

58

377

0

0

6

81

784

0

0

7

104

1577

0

0

7

130

2464

0

0

7

153

2734

0

0

8

172

3203

0

0

8

192

3562

0

0

8

203

3559

0

0

7

200

3190

0

0

5

168
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As shown in Table 17, it is clear shown the liver cancer incidence data from NCI/NIH
SEER data gives very high cancer rates at birth and before 5 years old.

Figure 18. A Multiple-Pathway Model for HBL and HCC
To account for inherited cancer cases in the stochastic model for liver cancer, we take
hereditary segregation into consideration for the population. Let p be the frequency of the
mutated APC gene (denoted by a) in the population, so that q = 1-p is the frequency of
the normal APC allele in the population (denoted by A). Assume that population is very
large and that mating (marriage) between people is random respect to the HBL-related
APC locus. Then by the Hardy-Weinberg law (Crow & Kimura, 1970; Tan, 2002) the
frequency of individuals with genotype aa, Aa and AA at the embryo stage in the
population are given by p2, 2pq and q2, respectively. The individuals carrying aa (both
APC alleles are mutated) genotype will developed liver cancer (HBL) at birth. Similarly,
the individuals carrying one mutated APC allele (Aa genetype) require mutation A → a
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during pregnancy to become individuals with genotype aa at birth. We use α to represent
the probability of A→a transition. It follows that the probability of individuals with
genotype Aa at birth is 1-α. α is usually small (10-3~10-2). On the other hand, for the
individuals with both normal APC alleles (AA genotype), the probability of two A → a
transitions to aa genotype is very small, we ignore those transitions in our model, and
assume that individuals with AA alleles are still normal at birth. However, HBL can be
developed through mutation of APC gene after born, therefore, there are two pathways
associated with HBL: for individuals born with Aa genotype, the HBL is developed
through one stage (Aa → aa); for individuals born with AA genotype, the HBL is
developed through two stages (AA → Aa → aa). The overall pathways of developing
liver cancer, including inherited HBL and non-hereditary liver cancer, are schematically
shown in Figure 18.
Because the number of stages and hence the probability distribution of time to cancer
tumors for each individual depend on the genotype of the individual at the embryo stage,
we let A

t (j = 1, 2) denote the number of Aj cells at time t in people who have

genotype i at the embryo state, with i =1for genotype aa, i = 2 for genotype Aa, and i =3
for genotype AA, respectively. Since the number of stages, through which HBL is
developed, depends on genotype at the embryo state, it follows that j = 1 for A
= 1, 2 for A

t . Similarly, we write {

number of new proliferated A

,

,

,

1, 2,

cells, number of deaths, number of mutants of A

at time t for genotype i, and number of tumors developed from genotype i.
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t , and j
} for
cells

The One-Stage Model and Mathematical Analysis
As shown in Figure 18, if an individual has genotype Aa at embryo stage, then one
stage is required to developed HBL (aa genotype). This is a one stage model given by
(Aa genotype) →

(aa genotype) → Tumor. For this person, the probability is α

that he/she would develop tumor at birth, the probability that he/she will remain Aa type
at birth is 1- α.
Because all stem cells at embryo stage are
person, the number of

(with Aa genotype) cells in this

cells can only be generated by stochastic birth and death of

these cells. It follows that the stochastic equation and the stochastic difference equation
t are given respectively by:

for the stage variable
Δ

(4.26)
Δ

Δ

Δ

(4.27)
Δ

where

Δ

Δ .

In the above equations, the conditional distributions of {

} given

0, and

is multinomial. It follows that
Δ

,

Δ , and

is uncorrelated with {

,

}.
Let f(x; N, p) denote the density of binomial distribution with parameters (N,p). From
equation (4.26), we obtain the transition probability of the Markov process
the order of o(Δt):
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as, to

∑

Δ

; ,

Δ

,

,

(4.28)
With

generated by the above stochastic equation, the number of tumor at time

t given number of primary A1 cells has Poisson distribution as follow:
|

,

~

(4.29)
,

where

.

Let QAa(j) denote the probability that an individual with genotype Aa at the embryo
stage develops cancer tumor during period (tj-1, tj] (j > 1). For individuals with genotype
Aa at the embryo stage, let

be the probability that this individual develops cancer

tumor during the period (tj-1, tj] (j > 1) via genotype Aa at birth. Then from equation
(4.29) and Figure 18, and
1
where

(4.30)

is given by:
, where
|

Let

is given above.

be the expected number of

for people

with genotype Aa at the embryo stage. Assuming ω1(t) = ω1 is very small, then
,

, where

(t > t0) is

From equation (4.27), the differential equation for
. So that
If

.

.
exp

, then
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, and hence

exp

,

and
(4.31)
exp

where

,

1 if

,

. If

1for t > x, then

0.

The Two-Stage Model and Mathematical Analysis
Assume that an individual has genotype AA at the embryo stage (a normal person).
Then for this individual all stem cells are normal cells at the embryo stage in which case
cancer tumors are derived by a two-stage model:

(AA genotype) →

(Aa

( aa genotype) → Tumor (as shown in Figure 18). The mutation rate

genotype) →

between AA and Aa is ω0(t), and the mutation rate between Aa and aa is ω1(t).
,

For this model, we use {

,

,

,

} to represent

random variables of number of birth, death, mutants, Aj cells and number of cancer
tumors developed from this two-stage pathway. The stochastic equations and the
stochastic difference equation for

cells are given as follow:

Δ

(4.32)
Δ
Δ

where

Δ

(4.33)

Δ

Δ
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Δ .

The normal cells (with genotype AA) increase or decrease only by stochastic birthdeath process. The stochastic equation and difference equation are the same as (4.26) and
(4.27). Similarly, the conditional distributions of the transition variables
,

,

are as follow:

given

~

Δ

,

|

(4.34)

~

;

Δ ,

Δ
(4.35)

Then it follows that

Δ

0, and

Δ

and

Δ ,

Δ

Δ

Δ

Δ

Δ .

(4.36)

Similarly, let f(x; N, p) denote the density at x of a binomial distribution with
parameter (N,p). Using the stochastic equation given by (4.26) and (4.32) and the
probability distributions given by equations (4.27) and (4.33), we obtain, to the order of
o(Δt):
Δ
∑

∑

,

; ,

Δ ,

Δ

;

Δ
(4.37)

As in last section, we have:
|
where

,

~

(4.38)
,

.
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Let QAA(j) denote the probability that an individual with genotype AA at the embryo
stage develops cancer tumor during period (tj-1, tj] (j > 1). For individuals with genotype
be the probability that this individual develops cancer

AA at the embryo stage, let

tumor during the period (tj-1, tj] (j > 1) via genotype Aa or AA at birth, and

be the

probability of individual born with Aa genotype but with AA genotype at embryo stage.
1

Similarly as in Section 4.4.1,
0, and

assume

, where we usually

is given in (4.30) and

is given by:
(4.39)

|

Let

,

1,2 be the expected number of

for people with genotype

Aa (u=1) an AA (u=2) at birth in people who have genotype AA at the embryo stage,
respectively. If ω1(t)= ω1 is very small, then, as in the section 4.4.1, we have, to the order
of o(ω1):
,

, where
Let’s derive

as shown in the last section, we have following equations:

|1

|1 e

|2

|2

e

ω x dx
1

,

|2

(Notice that
|1

and

(4.40)

|

where

|1

(4.41)
2

,

1,2.

|1

,

0) if αAA = 0).
,

If {

.

,

}, then (4.40) and (4.41) reduce to:

|1 e

(4.42)
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|2

|2 ω

e

dx

|2 e

ω /

.
(4.43)

Now

becomes

,

, where
|1

1

and

|2

is given
(4.44)

Then to the order of o(ω1):
(4.45)
Notice that if

,

1 for t > x, then
|1 e

reduces to
1

:
|2 e

1.
(4.46)

Statistical Model and the Probability Distribution of the Number of Detectable
Tumors for Hereditary Liver Cancer
The data available for modeling carcinogenesis are usually cancer incidence over
different time periods. For example, the SEER data of NCI/NIH for human cancers are
given by {(yj, nj), j = 1, . . . ,n}, where yj is the number of cancer cases during the j−th age
group and nj is the number of normal people who are at risk for cancer and from whom yj
of them have developed cancer during the age group. Given in Table 17 are the SEER
data for human liver cancer. From this data set, notice that there are a large number of
cancer cases before 10 year-old, which implies a large number of inherited cancer cases.
In this section, we will develop a statistical model for the data set.
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The Probability Distribution of the Number of Detectable Tumors for Different
Genotypes
To incorporate inherited cancer cases, among the nj people at risk for liver cancer, let
n1j be the number of individuals who have genotype aa at the embryo stage, n2j be the
number of individuals with genotype Aa at the embryo stage and n3j be the number of
individuals with genotype aa at the embryo stage. Then, from results in Section 4.5, the
conditional probability distribution of (n2j, n3j) given nj is multinomial with parameters
{nj; 2pq, q2}. It follows that n2j | nj ~ Binomial {nj, 2pq}.
Because y0 is the number of cancer cases at birth, which derive from individuals who
have genotype aa at the embryo stage, and we consider all individuals who have
genotype aa at the embryo stage will develop HBL at birth, so that expect number of
liver cancer cases at birth with genotype aa at the embryo stage is n0 p2.
To derive the probability distribution of yj (j ≥ 1) in the j-th age group, let y2j be
number of cancer cases generated with genotype Aa at embryo stage. The population who
have Aa genotype at embryo stage is n2j, and n2j given nj is binomial with parameter {nj,
2pq}, and as we have shown in section 4.5.1, each individual with Aa genotype at embryo
stage develops liver cancer though one-stage pathway with probability

(see

(4.30)). Then we can have:
| ~
where
Then

(4.47)
2

.
is the number of cancer case generated by the
people with genotype AA at the embryo stage. As we discussed in the

section 4.5.1, individuals who have genotype AA at the embryo stage usually born with
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normal, liver cancer developed either through two-stage AA → Aa → aa → Tumor, or
three-stage N → I1 → I2 → I3 → Tumor, or four-stage N → I1 → J1 → J2 → J3 →Tumor
as shown in Figure 18. The probability of an individual with genotype AA at the embryo
stage develops cancer tumor at j-th age group is
through three stage pathway, and

through two-stage pathway,

through 4-stage pathway, as shown in

(4.40) and (4.21), respectively. Then the probability of an individual developing liver
cancer through at least one of above three pathways is:
1

1

1

1

(4.48)

Similar as in section 4.4.1, it can readily be shown that to the order of Min{o(
o(

), o(

)},

),

.

Combine all genotypes together, the conditional distribution of yj given {nij, i = 2, 3;
2

nj} is Poisson with mean

. It follows that the

probability distribution of yj given nj is:
∑

;

,2

,

where
,
|

∑

|
,

~
,

~

,
,

;

,2

,

,

(4.49)

is the multinomial density of
;2

,

and

,

the Poisson density of

.

The probability given by (4.49) is a mixture of Poisson distribution with mixing
probability distribution given by the multinomial distribution of {

,

} given

. This

mixture distribution represents individuals with different genotypes at the embryo stage
in the population.

134

The Probability Distribution of the Mixture Model
Let Θ be the set of all unknown parameters in the mixture model (4.49). Based on
,

data (yj, j = 0,1, …, k), the likelihood function of Θ is
∏

|

0,1, … ,

.

In order to make inference about unknown parameters, we expand the model to
,

include the unobservable variables {

,

,

}. To derive the joint probability

distribution of these variables, observe that for j ≥ 1, the conditional probability of
,

{

,

} given {

{ ,

2, 3,

,
,

|

,

} is multinomial with parameters

}. That is,
,

2, 3,

,

~

,

,

(4.50)

for j ≥ 1.
Hence for j ≥ 1, the joint distribution of {
,
,

,
;

2, 3,
,2

,

,

0,1, … ,
,

,

,

2, 3,

} given

,Θ
,2

,

.
,

Put Y = (yij, i = 2,3, j = 1,…,k), N = (nij, i = 2,3, j = 1,…,k),
,

and

0, 1, … ,

is

. For the SEER data, the joint density

, ,

;

,

(4.51)
0, 1, … ,
| , Θ given

{ , Θ} is:
, ,
,

| ,Θ
∏

,

,2

,

,2

(4.52)
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Notice that the above distribution is a product of multinomial distributions and
Poisson distributions. For this join distribution, the deviances
2

, ,

| ,Θ

, ,

| ,Θ

is:

∑

(4.53)

where
2

log

log

2 2

2

log

1

log

1

2

log

(4.54)

The joint density

, ,

| , Θ given by (4.52) will be used as the kernel for the

Bayesian method to estimate the unknown parameters and to predict the state variables.
State Space Model and Estimation of Unknown Parameters
Unknown Parameters and Fitting of the Model by Cancer Incidence Data
,

In the above model, the unknown parameters are { , ,
0, 1, 2,

,

0, 1, 2,

,

,

,

,

,
,

,
}. Because

the mutation rates are very small, it is reasonable to assume all mutation rate are
homogeneous. Since the proliferation rate (i.e., birth rate – death rate) of normal stem
cells in individuals after birth is expected to be very small (Weinberg, 2007), so that we
assume that the number of stem cells of individual is a constant (~108).
To fit the SEER liver cancer data, we let one time unit (i.e., Δt=1) be 6 months after
birth. Then because the growth of last stage cells is very rapid, during a six months period
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one may practically assume

,

1 for

1. Then using this approximation,

we summarize probability of developing liver cancer from each pathway.
For individuals with aa genotype at embryo stage, the probability of developing HBL
at birth is 1.
For individuals with Aa genotype at embryo stage, as shown in section 4.5.1, the
probability of developing HBL during period (tj-1, tj] is:
(4.55)
where

and
1.

For individuals with AA genotype at embryo stage, as shown (4.45) and (4.46) in
section 4.5.2, the probability of developing HBL during period (tj-1, tj] is:
(4.56)
where

is given by (4.46).

For individuals with AA genotype (normal person) at birth, as shown in section 4.4.1,
the probability of developing HCC during period (tj-1, tj] through I-pathway (3 stages) and
J-pathway (4 stages) are:
(4.57)
where
~

(4.58)

~

(4.59)
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where

and

can be readily obtained, but

is very

complicate, we will use numerical way to get the approximation, which will be discussed
, where k1 = 3 for I-

in the next section. Here we only show how to derive
pathway. Let

1

represent

1

1

and

1 ,

represent

1
1 1

1 1
∑

1 1
1

∑

1

1

1 1

(4.60)

From all above results, it follows that the probability of developing liver cancer
depends on parameters through some functions of parameters, such as
. And also only proliferation rates

,

,

,

,

,

could be estimated.

However, since we assume the number of stem cells at birth for normal person (genotype
AA) and for person with Aa genotype are constant (~108), that is,
~10 ,

~10 ,

~10 , we can use Generalized Gibbs Sampling

method to obtain estimates for the mutation rates separately. The method used to estimate
parameters will be discussed in the next section. To simplify the notation, from now on,
we use AA to represent the
, for example,

in the superscribe of notations, and Aa to represent the
is represented by

.

State Space Model of Human Liver Cancer
State space model is a stochastic model which consists of two sub-models: The
stochastic system model which is the stochastic model of the system and the observation
138

model which is a statistical model based on available observed data from the system.
Thus, the state space model of a system takes into account the basic mechanisms of the
system and the random variation of the system through its stochastic system model and
incorporates all these into the observed data from the system; furthermore, it validates
and upgrades the stochastic model through its observation model and the observed data of
the system. As illustrated in Tan (2002, Chapters 8-9), the state space model has many
advantages over both the stochastic model and the statistical model when used alone
since it combines information and advantages from both of these models.
For human liver cancer (HBL and HCC), the stochastic system model of the state
space model is the stochastic multiple pathways model consisting of 5 pathways with
each pathway following a single-stage or a multi-stage model as described in Section 4.44.5; the observation model of this state space model is a statistic model based on the
observed number of liver cancer cases as described in Section 4.6.
The Stochastic System Model and the State Variables
Putting Δt = 1 for some fixed small interval, then the staging variables are X
={

,

,

1, … ,

1, … ,

,

}, the transition variables are U = {

,

} and population segregation variables are N = (nij, i = 2,3, j = 1,…,k). From

results in section 4.6, the joint probability distribution of {X, U } given the parameters Θ
and N is:
, | ,Θ

∏

|

1 ,

1 , ,Θ

1 |

1 , ,Θ
where

(4.61)
1 |

1 , , Θ and

|

1 ,

equations (4.18), (4.28) and (4.38) respectively, where Θ
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1 , , Θ are given by
,

,

,

,

0,1,2,

,

0, 1, 2,

,

,

1,2,

,

,

1,2,

. We assume the

model is time homogeneous, then all parameters are independent of time so that Θ =
{ , Θ , Θ , Θ }, where Θ = {
,

,

1,2,

,

,

,

0,1,

,

0, 1}, Θ = {

}, Θ

,

,

,

,

1,2,

.

Notice that this probability distribution is basically a product of Poisson distributions
and multinomial distributions.
The Observation Model Using SEER Data
Put Y = (yj, j = 1, . . . ,m) and N = (nij, i = 2,3, j = 1,…,k), by the probability
distribution given by equation (4.52), the conditional joint probability density of Y, N
given {X, U, Θ} is:
, | , ,Θ

, ,

| ,Θ

(4.62)

And above distribution is a product of multinomial distributions and Poisson
distributions. The deviance from above density has been given in (4.53).
From equations (4.61) and (4.62), we have following join density of (X, U, Y, N)
given Θ:
, , , |Θ
where

, , |Θ

, | , ,Θ

|Θ

(4.63)

|Θ is a multinomial distribution.

The Generalized Bayesian Method and the Gibbs Sampling Procedure
To fit the model to the data and to valid the model, one would need to estimate the
unknown parameters and to predict the state variable. We propose generalized Bayesian
inference procedures to achieve those purposes.
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The generalized Bayesian inference is based on the posterior distribution P{Θ|X, U,
Y, N } of Θ given {X, U, Y, N }. This posterior distribution is derived by combining the
prior distribution P{Θ} of Θ with the probability distribution P{X, U, Y, N | Θ } given
by equation (4.63). It follows that this inference procedure would combine information
from three sources:
(1) Previous information and experiences about the parameters in terms of the prior
distribution P{Θ} of the parameters.
(2) Biological information via the stochastic system equations of the stochastic
system (P{X, U | N, Θ }) .
(3) Information from observed data via the statistical model from the system (P{Y, N
|X, U, Θ}).
Because of additional information from the stochastic system model, this inference
procedure is advantageous over the standard Bayesian procedure in that it can avoid the
identifiability problems associated with standard Bayesian method. For example, we have
shown that to the order of Max{o(

), o(

), o(

)} the probability distribution

of the yj’s depends on the stochastic model through the expected numbers of I2(t), J2(t),
and

, which depend on function of mutation rates (as shown in section 4.7.1) as

well as the birth rates and death rates through the difference of these rates. It follows that
it is not possible to estimate the birth rates, death rates and mutation rates separately by
the traditional Bayesian method. Most importantly, the number of parameters is very
large and the number of data points is limited. Thus, without information from the
stochastic system model, it is virtually impossible to estimate all unknown parameters;
for more examples, see Tan (2000, 2002). Notice that if one uses the standard Bayesian
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inference procedure by combining the prior with the density P{Y, N |X,U,Θ}, then
because the density P{Y, N |X, U,Θ} depends on the birth rates and the death rates only
through the differences of these rates, it is not possible to estimate the birth rates
(

,

,

1,2) and death rates (

,

,

1,2) separately but only the proliferation

rates (the difference between birth rate and death rate).
The Prior Distribution of the Parameters
For the prior distributions of Θ, because biological information have suggested some
lower bounds and upper bounds for the mutation rates and for the proliferation rates, we
assume
Θ

0

(4.64)

where c is a positive constant if these parameters satisfy some biologically specified
constraints; and equal to zero for otherwise. These biological constraints are:
(i) To ease the problem, we assume individuals with genotype aa at embryo stage
develop HBL with probability 1, and almost all of HBL cases at birth are from
individuals with genotype aa at embryo stage. Then the frequency of individuals with
genotype aa at the embryo stage in the population p2 can be approximately determined by
rate of HBL cases among all population at birth.
(ii) For the mutation rates of the Ii cells in the first pathway (i.e., the N → I1 → . . . →
→ tumor pathway), 1 < N0 * α0 < 1000 (N → I1), 10−8 < αi < 10−3, i = 1, 2, where N0
= 108. For the proliferation rates of Ii cells in the I-pathway, 0 <
<

< 0.2,

<

.
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< 0.5, i = 1, 2, 10−4

(iii) For the mutation rates in the J-pathway (i.e., the N → I1 → J1 → . . . →

→

tumor pathway), 10−8 < βj < 10−3, j = 0, 1, 2. For the proliferation rates in the second
< 0.5, 10−4 < (

pathway, 0 <

< 0.2,j = 1, 2,

<

.

(iv) For the mutation rates in the AA-pathway (i.e., the AA → Aa → aa → tumor
pathway), 10−10 < ωk < 10−4, k = 0, 1. For the proliferation rates of Aa cells, 0 <
< 10-3, and 10−6 <

< 10-3.

(v) From information from Section 4.2, αi < βi ,

<

, i = 1, 2.We will refer the

above prior as a partially informative prior which may be considered as an extension of
the traditional non- informative prior given in Box and Tiao (1973).
The Posterior Distribution of the Parameters Given {Y,X, U, N}
Combining the prior distribution given in section 4.8.1 with the density of P{X,U,Y,
N |Θ} given in equation (4.63), one can readily derive the conditional posterior
∑

distribution of Θ given {X,U,Y, N }. For (i = 1, 2), denote by:
∑

and

replacing (
∑

,

∑

; similarly, for j = 1, 2, we define {

,
,

,

) by (
∑

,

,

and

,

,

} by

), respectively. We also define
∑

. For i = 1, 2, put

,

and

. Then, we have the following results for the conditional
posterior distributions:
(i) The conditional posterior distributions of Θ = {
given {X, U, Y, N} is:
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,

,

0,1,

,

0, 1}

Θ | , , ,
Θ
(4.65)
The conditional posterior distributions of Θ ={

(ii)
1,2,

,

,

,

1,2,

,

,

} given {X, U, Y, N } is:

Θ | , , ,
,

Θ

; ,

,

∏

,

;

,

,

,

;

,

,
(4.66)

where f(x, y; N, p, q) is a multinomial density with parameters (N, p, q).
(iii) The conditional posterior distribution of Θ

,

,

given {X, U, Y, N }

is:
,

,

| , , ,

Θ

∏

(4.67)

where m is the number of time units between t0 to tM.
The Multi-level Gibbs Sampling Procedure for Estimating Parameters
Given the above probability distributions, the multi-level Gibbs sampling procedure
for deriving estimates of the unknown parameters are given by:
(a) Step 1: Generating (X,U, N) Given (Y , Θ) (The Data-Augmentation Step):
Use computed ̂ (p be the frequency of the mutated APC gene (denoted by a) in the
population) to segregate the population into three groups: AA group consists people who
are normal at birth, Aa group consists of all individuals with Aa genotype at birth, and aa
group consists of individuals with aa genotype at birth. Given Y and Θ, use the stochastic
equations (4.1), (4.2), (4.32) and the probability distributions given by equations (4.3) 144

(4.8) and (4.34) - (4.36) in Section 4.3 and 4.4 to generate a large sample of (X,U). Then
by combining the sample with P{Y |X, U, Θ, N}, (X, U) are selected through the
weighted bootstrap method proposed by Smith and Gelfand (1992). This selected (X, U)
is then a sample from P{X,U|Y , Θ } even though the latter is unknown. (For proof, see
Tan (2002), Chapter 3.) Call the generated sample ( , ).
(b) Step 2: Estimation of Θ = {Θ , Θ , Θ } Given {Y ,X, U}:
Given Y and given (X,U) = ( ,

) from Step 1, derive the posterior mode of the

parameters by maximizing the conditional posterior distribution P{ Θ | , , , ̂ }.
Denote the generated mode as .
(c) Step 3: Iterative Step.
With {(X, U) = ( , ), Θ = } given above, go back to Step (a) and continue until
convergence.
The proof of convergence of the above steps can be proved using procedure given in
Tan (2002) (Chapter 3). At convergence, the

are the generated values from the

posterior distribution of Θ given Y independently of (X,U) (for proof, see Tan (2002,
Chapter 3). Repeat the above procedures one then generates a random sample of Θ from
the posterior distribution of Θ given Y ; then one uses the sample mean as the estimates
of Θ and use the sample variances and covarainces as estimates of the variances and
covariances of these estimates.
Application to Fit the SEER Data
In this section, we will apply the above model to the NCI/NIH liver cancer data from
the SEER project. Given in Table 17 are the numbers of people at risk and liver cancer
cases in all age groups, as well as predicted cancer cases by using our model. The cancer
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Table 18
Estimates of Parameters for Each Pathway
p = 3.48E-03

8.51E-04, α = 1.12 E-05

1.03E-05

AA → Aa → aa → tumor pathway
AA → Aa (ω0)
Mutation rate

3.98E-08

1.11E-09

Aa → aa (ω1)
1.27E-05

Aa

6.96E-08
aa

Birth Rate

4.33E-04

1.89E-05

N/A

Death Rate

3.92E-04

3.07E-05

N/A

I-Pathway (N→ I1 → I2 → I3 → tumor)
N→ I1 (N0α0)
Mutation rate

3.88

0.14

I1 → I2
4.36 E-03

I1

9.99E-04
I2

I2 → I3
1.16E-06
1.33E-07
I3

Birth Rate

7.48E-03 2.24 E-03

1.2 E-02

1.26E-03

N/A

Death Rate

4.43E-03 2.55 E-03

9.07E-03

6.12 E-03

N/A

J-Pathway (N→ I1 → J1→ J2 → J3 → tumor)
I 1 → J1
Mutation rate

4.37E-03

1.35E-03

J1 → J2
3.67E-03

J1

1.82E-03
J2

J1 → J2
2.80 E-05
7.41E-07
J3

Birth Rate

2.14E-02

2.83E-03

2.86E-02

1.48E-02

N/A

Death Rate

1.38E-02

3.39E-03

4.37E-03

5.43E-03

N/A

146

cases developed from each pathway are also predicted and show in Table 17. There are
18 (m = 18) age groups with each group spanning over 5 years except at birth.
Given in Table 18 are the estimates of the mutation rates, the birth and death rates of
the Ii cells, Jj cells AA cells and Aa cells. Given in Figure 19 is the plot of the observed
and predicted cancer incidence and Figure 20 the probability distributions of time to
tumors from each pathway.
From these results, we have made the following observations:
(a)

As shown by results in Table 17, the predicted number of cancer cases are very

close to the observed cases. The AIC (Akaike Information Criteria) and the BIC
(Schwarz Bayesian Information Criteria) are given by 66.23 and 87.94 respectively. This
indicates that the model fits the data well and that one can safely assume that the adult
human liver cancer can be described by a model of multiple pathways as given in Figure
18. It fits also considerably better than single pathway models. The AIC and the BIC of
the best fitted single pathway model (i.e., the 4-stage single pathway model) are given by

Figure 19. Observed and Predicted Liver Cancer Cases
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316.0184 and 326.2786 respectively.
(b)

Most of individuals with Aa genotype at embryo stage develop liver cancer

before 20 year-old, which is consistent with clinical results (Hirschman, Pollock, &
Tomlinson, 2005). If individuals are born with normal, most of liver cancer is developed
through I-pathway and J-pathway, that is, environmental effect play the most important
role for adult liver cancer.
(c)

From Table 17, it is observed that the largest number of cancer cases is in the

age group between 65 and 75 years old. Most of liver cancer cases develop liver cancer
through J-pathway though one more pathway is needed for J-pathway than the I-pathway.
As shown parameters estimate in Table 18, the higher mutation rates for I1 → J1 and J1

→ J2, as well as higher proliferation rates for J1 and J2 account for the difference.
(d)

Results in Table 18 showed that the mutation rates from I1 → J1, from J1 → J2

Figure 20. Density of Time to Tumor for Each Pathway
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and from J1→ J2 are e about 10 times greater than the mutation rates from I1 → I2 → I3.
These results might be the consequence that the J-pathway has accumulated more genetic
and epigenetic changes (see Pogribny, Rusyn, & Beland, 2008; Villanueva et al., 2007).
(e)

Results in Table 18 showed that the estimates of the birth rates of J2 cells were

about 10 times greater than those of I2 cells. The estimate of proliferation rate (birth rate death rate) of the J2 cells is around 4 times of that of J1 cells. These estimates are about
10 times greater the estimates of the proliferation rates of I2 cells (2.42E-02 and 0.3E-02,
respectively). Notice that the estimate of the birth rate of I2 cells is 0.012 which is greater
than the estimate 0.00748 of I1 cells but the estimate of death rate of I2 cells is 0.00907
which is much greater than the estimate 0.00443 of I1 cells, due presumably to effects of
apoptosis (Notice that apoptosis is usually a late event in carcinogenesis.). This may help
explain why the proliferation rate of I2 cells is about equal to (or a little smaller than) that
of I1 cells. Notice also that the estimates of the proliferation rates of Ji (i = 1, 2) cells are
of order 10−2 (proliferation rate for J1 is 0.0076, which is slightly smaller than 10-2)
whereas those of Ii (i = 1, 2) cells are of order 10−3. These results clearly reflect the
biological observation that more genetic and epigenetic changes have accumulated in the
J-pathway than in the I-pathway (Pogribny et al., 2008; Villanueva et al., 2007).
Conclusion and Discussion
Recent studies of cancer molecular biology have indicated very clearly that human
liver cancer is developed through multiple pathways (Grisham, 2002), and the cancer
mechanisms for pediatric liver cancer (HBL) are different from adult liver cancer (HCC)
(Hirschman et al. 2005). This indicates that single pathway models are not realistic and
hence may lead to incorrect prediction and confusing results. For developing efficient
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prevention and controlling procedures for human liver cancer and for prediction of future
human liver cancer, in this chapter we have developed a stochastic model and a state
space model for carcinogenesis of human liver cancer involving multiple pathways
incorporating hereditary liver cancer, with each pathway being a multi-stage model.
Using this model, we have derived for the first time the probability distribution of the
numbers of initiated cells and the probability distribution of time to cancer tumors for
each pathway. Such derivation by the traditional approach is extremely difficult and had
not been attempted previously for liver cancer involving single pathway models and
multiple pathway models.
Based on the state space model of liver cancer, we have developed a generalized
Bayesian procedure to estimate the unknown parameters and to predict future cancer
cases. This approach combines information from three sources: The stochastic system
model via P{X, U, N | Θ}, the prior information via P{Θ} and information from data via
P{Y | N ,X, U, Θ}. Because of additional information from the stochastic system model,
our procedure is advantageous over the standard Bayesian procedure and the sampling
theory procedure. For example, for the first time we can estimate the birth rates and death
rates separately for all pathways which are not possible by the classical Bayesian
methods or sampling theory methods. Notice that there are a large number of unknown
parameters in the model and only a limited amount of data are available. Without this
additional information, it is then not possible to estimate all unknown parameters. Notice
also that through the stochastic system model, one can incorporate biological mechanism
into the model. Because the number of stages and the mutation rates of intermediate cells
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in different pathways are different and different drugs may affect different pathways, we
believe that this is important and necessary.
We have applied this model and methods to the NCI SEER data (up-to November,
2008). Our results showed that the proposed multiple-pathway model fit the data
remarkably well. The estimates from the model are strongly consistent with biological
findings.
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5. SUMMARY AND FUTURE RESEARCH

We have developed stochastic models and statistical models and hence state
space model for carcinogenesis under complex situations (i.e., multiple-pathway
multiple-stage model).
In chapter 1, we have used a simple two-pathway model with one pathway
involving a single stage model and the pathway involving a three stages model to
assess the classical two-stage Markov model (MVK model) for carcinogenesis; we
have derived the incidence function and have revealed many difficulties and
drawbacks of the traditional MVK model. To overcome these difficulties we have
introduced stochastic difference equation method and have used the generalized
Bayesian procedure to estimate unknown parameters. In this chapter we have
briefly revealed the complex nature of carcinogenesis.
In chapter 2, we have developed stochastic models for the three commonly
used experiments in bioassay in the area of cancer risk assessment of
environmental agents: The initiation, the promotion and the complete experiments.
We notice that the stochastic process for each experiment is unique and each can
be represented by an unique multiple-pathway model. Most of these stochastic
models are simple processes. For initiation experiment, the model is a twopathway model with one stage for each pathway whereas for promotion and for
complete experiments, the models are two-pathway model with one stage for one
pathway and with two stages for the other pathway. A generalized Bayesian
procedure was developed to estimate unknown parameters. Simulation study
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shows that the models are quite reliable and estimates are very close to true (given)
parameter values.
In chapter 3, based on biological information, we have developed a twopathway model for sporadic human colon cancer; one pathway has 4 stages, and
the other has 5 stages. Using this as the stochastic system model, we have
developed a state space model with the observation model being a statistic model
based on cancer incidence data relating the model to the system. In this model,
biological information are effectively captured by a stochastic system model and
cancer incidence are effectively linked to the system through the observation
model. We have fitted the model to the NIH/NCI SEER data. The fitting results
have revealed that the multiple-pathways model not only fit the observed incidence
data better than the single 4-stage model, but also are consistent with biological
findings.
In chapter 4, we have further extended the state space model to handle more
complicated multiple-pathway carcinogenesis of human liver cancer incorporating
hereditary and non-hereditary cancer incidence. Cancer heredity has been well
known to account for pediatric liver cancer, also known as hepatoblastoma (HBL).
The mechanism of developing HBL is different from cancer for adult, usually
known as hepatocellular carcinoma (HCC). For HBL, the major mutated gene is
APC, and for HCC, liver cancer is developed through two pathways with multiple
stages for each pathway. We segregated the population by using the frequency of a
major mutated gene (APC gene) into three subgroups, and for each subgroup, we
constructed stochastic model accordingly. In combination of generalized Bayesian
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approach using multi-level Gibbs sampling procedures, we have estimated the
segregation frequency as well as mutation rates, birth rates and death rates for all
stages. The model predicted cancer incidences of all age groups very well, and
through the parameters estimated from the model we have also predicted the
number of cancer cases for each cancer subgroups for each age group, as well as
density of time to tumor for each pathway.
Overall, we have developed innovative stochastic and state space models for
multiple-pathway carcinogenesis. We have developed models to assess bioassay’s
effect in tumor development, models to evaluate tumor development for colon
cancer, and models for inherited and non-inherited liver cancer. The stochastic and
state space models we have developed have many advantages over the traditional
Markov multistage models, and are more consistent with biological information;
these models are based on biological information and hence are more realistic and
applicable in practice.
So far our study in risk assessment has only concentrated on time to tumor
(papillomas and/or carcinomas); we have not extended the models to cover
progression of papillomas and carcinomas. For future research, we will proceed to
develop models to cover tumor progression; for these purposes we need to
consider correlation between cases at two time points during tumor progression.
Thus, for the initiation-promotion bioassay, our future work will cover developing
state space model for longitudinal observations involving tumor progression.
The stochastic and state space models for carcinogenesis are still exploratory,
and the models we developed have been applied for overall population, not for
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small cohort. With more biological information discovered in molecular biology,
cancer genetics, and cancer clinic, we will develop stochastic and state space
models for more specific population group. In the future, we will also incorporate
treatment protocols into models for colon cancer, liver cancer or other types of
cancers to provide quantitative evaluation of treatment effects.
We have not predicted the cancer cases for the future time points. Thus,
another future research subject is to develop predictive inference for cancer
incidence and progression. We will access the predictive inference through two
ways: Bayesian prediction and Kalman filter prediction. The Bayesian prediction
is basically updating the posterior distribution of parameters by introducing the
new sets of observations and newly updated prior distribution whereas the Kalman
fitter prediction is based on construction of smoothing prediction function. We will
compare these two predictive inferences to give more insight of prediction
precision as well as to validate the models.
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